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GENE EXPRESSION PATTERNS IN PATIENTS WITH HIGH-ALTITUDE
PULMONARY EDEMA: A GENE MICROARRAY ANALYSIS. Lauren Kendall
Krause and Robert Roach, Colorado Center for Altitude Medicine and
Physiology, Section of Emergency Medicine, Department of Surgery, University
of Colorado Health Sciences Center, Denver, CO. (Sponsored by Keith J.
Ruskin, Department ofAnesthesiology, Yale University School ofMedicine, New
Haven, CT)
Multiple modulating genes and environmental factors have been
implicated in the pathogenesis of high-altitude pulmonary edema (HAPE).
However, at the present time, there exists an incomplete understanding of the
molecular mechanisms and pathways which underlie constitutional
susceptibility. Genome-wide measurements of gene expression in peripheral
blood mononuclear cells (PBMCs) were performed using microarray technology.
Comparison of gene expression profiles of HAPE- susceptible and resistant
individuals resulted in the identification of several previously undescribed
candidate genes. RhoA and Rho-kinase (ROCK), regulators of vascular smooth
muscle contraction, were differentially regulated in the HAPE-susceptible
cohort, as compared to both HAPE-resistant patients with acute mountain
sickness (AMS+) and healthy controls (p =0.0014; p
=
0.0020). Furthermore,
biological pathways involving RhoA and Rho-kinase were strongly upregulated
in subjects with HAPE. These findings represent the first description of the
RhoA/Rho-kinase signaling pathway in HAPE. Currently, few pharmacologic
therapies have been demonstrated to be effective in the prevention and
treatment of HAPE. The results of this study provide early evidence that
Fasudil, a selective Rho-kinase inhibitor, may represent a novel therapeutic
intervention effective in the prevention and/or treatment of high-altitude
pulmonary edema.
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Millions of people live, work, and travel to areas above 8000 ft (2500 m)1,
and worldwide, over 140 million people permanently reside at altitudes higher
than 2500 m2. Medical problems that result from difficulty adapting to life at
high altitude and the effect of high altitude on preexisting medical conditions
have therefore become important fields of research.
For over 200 years, scientists have attempted to elucidate the
mechanisms by which man adapts to hypoxic stress. As a result, the
physiologic changes that occur in response to the hypoxia of high altitude have
been well described, however, the pathophysiology that underlies maladaption
is not yet well classified. Maladaption syndromes comprise a continuum of
"high-altitude related illness" from the relatively common and benign acute
mountain sickness (AMS), to the rare and life threatening high-altitude
pulmonary edema (HAPE) and high-altitude cerebral edema (HACE)1' 3.
The study of high-altitude illness allows researchers to develop models
for the pathophysiological effects of hypoxia on healthy individuals3.
Additionally, the physiological effects of hypoxia are seen in many important
cardiopulmonary diseases, including chronic obstructive pulmonary disease,
pulmonary hypertension, congenital heart diseases, and valvular disease4.
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HISTORY
Humans have been aware of the physiologic effects of high altitude for
over 2000 years. As early as 37 BC, a classic Chinese text, the Ch'ien Han Shu,
references "Great Headache Mountain" and "Little Headache Mountain" along
the route of the ancient Silk Road between China and modern Afghanistan.
"Again on passing the Great Headache Mountain, the Little Headache
Mountain, the Red Land and the Fever Slope, the men's bodies become feverish,
they lose colour and are attacked with headache and vomiting; the asses and
the cattle all being in like condition."5 The Greeks attributed the illness that
befell them upon climbing to the summit of 29 19 m Mount Olympus as a sign
that mere mortals were not fit to stand on the mountain.
The first known description of acute mountain sickness in Western
culture is by Father Jose de Acosta, a Jesuit priest who accompanied the
Spanish Conquistadors in Peru in 1590. While crossing the Andes via the
15,750 ft (4800 m) pass at Pariacaca (now known as Tullujuto)6, en route to the
high plateau region, many of the travelers became sick. He describes being
"suddenly surprised with so mortal and strange a pang, that I was ready to fall .
. . the air is there so subtle and delicate, as it is not proportionable with the
breathing of man." He also described increased susceptibility amongst those
ascending from sea level, versus those who had spent time on the high plateau
of the Altiplano. He describes "strange intemperatures, yet more in some
parties than in others and rather to those which mount from the sea, than from
the plaines."5
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The hazards of traveling through high-altitude areas were also described
by Mirza Muhammed Haider, a Mongol chieftain who led his troops through
Asia and Tibet.
Another peculiarity of Tibet is the dam-giri which the Moghuls call
Yas and which is common to the whole country, through less
prevalent in the region of forts and villages. The symptoms are a
feeling of severe sickness (nakhushi) and in every case one's
breath so seizes him that he becomes exhausted, just as if he had
run up a steep hill with a heavy burden on his back. On account
of the oppression it causes it is difficult to sleep. Should, however,
sleep overtake one, the eyes are hardly closed before one is awake
with a start caused by the oppression of the lungs and chest. . .
When overcome by this malady, the patient becomes senseless,
begins to talk nonsense, and sometimes the power of speech is
lost, while the palms of the hands and the soles of the feet become
swollen. Often, when this last symptom occurs, the patient dies
between dawn and breakfast time; at other times he lingers on for
several days . . . This malady only attacks strangers; the people of
Tibet know nothing of it, nor do their doctors know why it attacks
strangers. Nobody has ever been able to cure it. The colder the
air, the more severe is the form of the malady7.
THE ENVIRONMENT
As altitude increases, barometric pressure falls in a logarithmic fashion,
resulting in a net decrease in the partial pressure of oxygen. The relative
contribution of gases to the earth's atmosphere is fairly constant from sea level
to 300,000 ft (91,400 m), consisting of 78% Nitrogen and 21% Oxygen. As
barometric pressure decreases, so too does the partial pressure of oxygen. This
phenomenon is in accordance with Dalton's Law, which states that the total
pressure of a mixture of gasses is equal to the sum of the pressure exerted by
each gas in the mixture (PT
= PI + P2 + P3. . .). Thus, the partial pressure of O2
decreases with barometric pressure. For example, at sea level (barometric
pressure
=
0), the ambient 02 is 760 mmHg; at 5000 ft (1500 m; barometric
pressure
=
633), the ambient 02 is 133, and at 10,000 ft (3000 m; barometric
pressure
=
523), the ambient O2 is 110 mmHg, or approximately 69% of that
available at sea level. At the summit of Mt. Everest (29,000 ft), the inspired
pressure of oxygen is only 28% of that at sea level4.




Sea Level (0) Sea Level (0) 760 101
1000 3,280 679 90
1500 4,921 641 88
2000 6,561 605 80
2500 8,201 570 75
3000 9,842 537 71
3500 11,482 506 67
4000 13,122 476 63
4500 14,763 447 59
5000 16403 420 55
5500 18,044 394 52
6000 19,684 370 49
7000 22,965 325 43
8000 26,245 284 37
8839 28,998 253 33
"High" altitude is often subdivided into three distinct subdivisions, each
with specific physiologic effects: high altitude, very high altitude, and extreme
altitude. High altitude is defined as those altitudes between 1500 m and 3500
m (4900-1 1,500 ft), and is the elevation at which the human body begins to
respond to hypoxia. In aviation, this physiologic division is known as the
efficient zone, defined as the altitudes at which humans can adapt to the
reduced ambient PO2 using normal physiological mechanisms. These
physiologic adaptations, which will be discussed later, include increased
ventilation, increased cardiac output, and decreased exercise performance.
Some individuals experience symptoms of acute mountain sickness (AMS),
including headache, nausea, decreased appetite, lightheadedness, and fatigue.
Within 24-72 hours, susceptible individuals may become ill with high-altitude
pulmonary edema, which is a form of non-cardiogenic pulmonary edema.







Very high altitude extends from 3500 m to 5500 m (1 1,500-18,000 ft).
While most healthy individuals can sustain relatively normal oxygen
saturations at "high altitude," at these altitudes, oxygen saturation in normal,
unacclimatized individuals almost uniformly falls below 90%. This hypoxemia
can result in the symptoms ofmore severe altitude illness, including severe
AMS, high-altitude pulmonary edema, and high-altitude cerebral edema.
Extreme altitude encompasses any altitude exceeding 5500 m (> 18,000
ft). At these altitudes, the ability of the human body to adapt physiologically to
the extreme hypoxemia can result in severe illness. Humans who ascend above
5500 m must acclimatize, or they are at risk for development of severe, life-
threatening altitude illness. Both very high and extreme altitude fall into the
physiologic deficient zone, in which physiologic compensatory mechanisms are
insufficient to maintain normal oxygen saturation.
Many people have attempted to identify the highest permanent human
settlement in order to determine the degree of hypoxia that humans can tolerate
on a permanent basis. It has been suggested that the limit of permanent
acclimatization lies somewhere between 16,000 and 20,000 ft (4877 to 6096 m),
depending on other environmental factors8. A survey by West (2002) concluded
that the highest permanent human settlement is at the mine of La Rinconada, a
Peruvian village with a population of approximately 7000 people, who have lived
at 5100 m (16,730 ft) for over 40 years9. Other reports suggest that humans
have lived as high as 5950m (19,520 ft) for two years.
PHYSIOLOGICAL ADAPTATION
Acclimatization, the physiological adaptation of an animal to changes in
climate or environment, such as light, temperature, or altitude, allows for
adaptive changes which increase humans' tolerance of low-oxygen states.
Human beings are able to gradually adjust to hypoxia at high altitude through
a variety of physiological mechanisms allowing for improved oxygenation and
enhanced performance and survival in hypoxic surroundings. These
mechanisms vary from the activation of basic cellular functions to complex,
coordinated physiologic pathways.
Hypoxia is defined as a deficiency in the amount of oxygen available in
the blood or reaching the body's tissues. It can result from four different types
of pathophysiological disturbances 10. The first, hypoxic hypoxia, is the result of
decreased oxygen concentration in the air (as seen at high altitudes) or
decreased ability of oxygen to diffuse across the alveolar wall
—in both
scenarios, the arterial oxygen saturation will fall below 100%. Reduced oxygen
carrying capacity of the blood, as seen with anemia and carbon monoxide
poisoning, results in hypemic hypoxia. Reduced or insufficient cardiac output
causes stagnant hypoxia. The fourth, or histotoxic hypoxia results when the
tissues are unable to adequately extract and utilize oxygen from the blood. This
can be seen in the setting of any toxin which decreases the cellular respiratory
rate, typically alcohol and cyanide poisoning.
As individuals ascend to higher altitudes, they generally experience four
"stages" of hypoxia: indifferent, compensatory, disturbance, and critical10. At as
low as 1500 m, the effects of hypoxia may begin to take place, though they may
not be apparent to the individual. The first physiologic derangement is
decreased ability of the eye to discriminate between dark and color. During the
compensatory stage, the body is able to make adequate compensation for the
hypoxic stress through increased heart rate, cardiac output, blood pressure,
8
and respiratory rate. The disturbance stage is characterized by physical
symptoms resulting from an inability of the body to adequately respond to the
hypoxic challenge. Finally, the critical stage is characterized by loss of
consciousness. This stage is more common in aviation medicine, in which
individuals can be transported to very high altitudes, very quickly.
Oxygen is an essential part of the electron transport chain and is
required for normal cellular function. The discovery of hypoxia-inducible
factor- 1 (HIF-1), a heterodimer protein which regulates gene transcription,
highlights the way in which basic cellular functions adapt to low oxygen states.
In the hypoxic cellular environment, HIF- 1 binds to specific hypoxic-responsive
sequences, thus activating transcription of various growth factors, glycolytic
enzymes, and vasoactive peptides11. The fact that HIF-1 influences the
expression of approximately 5% of human genes demonstrates the important
role adaptation to hypoxic conditions has played in natural selection and
evolution.
Ventilation
The most important adaptive response in the process of acclimatization
is increased minute ventilation. Hypoxia induces predictable ventilatory
changes, including hyperventilation and increased tidal volume12, critical to
successful acclimatization13.
Low arterial blood P02 is sensed by the peripheral chemoreceptors, most
importantly the carotid body, which in turn stimulates the respiratory control
center in the medulla, which drives the ventilatory response. Several studies
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have demonstrated a blunted ventilatory response to hypoxia following
denervation of peripheral chemoreceptors14.
This increased ventilation, termed hypoxic ventilatory response (HVR)
acutely decreases relative hypoxemia by increasing minute ventilation, raising
alveolar oxygen tension, and improving oxygen delivery to peripheral organs.
This response is activated within the first few minutes after exposure to a
hypoxic stimulus, and may begin at as low as 1500 m. At extreme altitudes,
this response is robust
—
on the summit ofMount Everest (8,850 m), alveolar
ventilation increases approximately 5-fold15.
Increased ventilation results in a predictable reduction in alveolar and
arterial PCO2, resulting in a respiratory alkalosis. The metabolic compensatory
response for this respiratory alkalosis occurs though increased renal excretion
of bicarbonate and takes 2-3 days. Thus, in the period of time between the
initial exposure and the development of an adequate compensatory metabolic
response, individuals may actually develop a maladaptive alkalosis-induced
inhibition of respiratory drive.
Acetazolamide is a carbonic anhydrase inhibitor commonly used for
prophylaxis and treatment ofAMS, and improves acclimatization by exploiting
this pathway. It indirectly stimulates ventilatory drive by increasing renal
bicarbonate excretion, thus returning arterial pH towards normal and reducing
the inhibition of ventilation resulting from the respiratory acidosis.
The magnitude of an individual's ventilatory response to hypoxia is
influenced both by intrinsic, genetic and external factors. Brisk HVR at low
altitude appears to predict successful acclimatization upon ascent to high
altitude. Twin studies, in addition to cases of familial clustering of ventilatory
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responsiveness, suggest that genetic factors influence ventilatory response to
hypoxia, and therefore acclimatization to altitude. These genes may be involved
in regulation of the sensitivity of the peripheral chemoreceptors to hypoxic
stimuli, ion channels, or regulation of other intrinsic hormonal or metabolic
factors.
Cardiovascular
High-altitude residents and individuals who remain at high-altitudes for
extended stays develop increased erythrocyte production, and eventually,
polycythemia. This adaptive response, mediated by increased concentrations of
2,3-diphosphoglycerate (2,3-DPG), results in an increased capacity of the blood
to carry and deliver oxygen. The erythrocyte production rate increases within
several days, but the new steady state is not reached for several weeks16. This
process does not play an important role in early adaptation, though it may be
implicated in Chronic Mountain Sickness, a syndrome characterized by
polycythemia which affects high-altitude residents. Individuals who have
recently ascended to high-altitude are often noted to have an increased
hematocrit, though this is likely due to altitude-induced dieresis and increased
fluid losses.
As inspired PO2 decreases, the body's maximal oxygen consumption is
also reduced; at an altitude of 3000 m (9800 ft), it is reduced to 85% of sea-level
values. On the summit of Everest, maximal consumption falls to a mere 20% 17,
resulting in reduced exercise tolerance, as well as extreme fatigue. While this




Successful acclimatization is influenced by many factors, including the
severity of hypoxemia, rate of ascent, total altitude gained and individual, likely
genetic, factors. It is known that an individual's tendency to acclimate poorly
(or well) is fairly consistent across time. That is, given repeated exposures, an
individual who has suffered from altitude related problems in the past is more
likely to do so again1. Furthermore, certain individuals are more likely to
develop severe illness at moderate altitudes18 19.
Much research has focused on the pathophysiology underlying
maladaptive responses to hypoxia. Current evidence points towards the role of
relative hypoventilation in altitude maladaption syndromes. Individuals who
develop HAPE have a poor ventilatory response to hypoxic stress, as measured
by HVR2022. Additionally, individuals who are prone to develop AMS tend to
have greater resting arterial hypoxemia and exaggerated hypoxemia following
hypoxic challenge than do their non-susceptible counterparts22' 23. In these
cases, the degree of hypoxemia is predictive of the likelihood of developing AMS
with ascent. Some studies have reported an inverse relationship between low
hypoxic ventilatory response and the propensity to develop altitude illness21- 24>
25
Inability to adapt to altitude appears to be an idiosyncratic occurrence.
Neither physical training, nor other identifiable traits have been found to be
predictive of, or protective against, its development.
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Acute Mountain Sickness and High Altitude Cerebral Edema
Altitude related problems form a spectrum from Acute Mountain
Sickness (AMS) to High-altitude Cerebral Edema (HACE). Although rapid
exposure to altitudes greater than 2500 m (8000 ft) will affect most individuals
to some degree, individual variation in the ability to effectively acclimatize is
significant. AMS is a self-limiting illness and is the most benign of the altitude-
related illnesses. It is thought to be part of a continuum that includes the life-
threatening diagnosis of HACE.
In theory, the pathophysiology underlying AMS is related to that causing
HACE, albeit to a less severe extent. All people who ascend to high altitude
experience some brain swelling26- 27. This mild cerebral edema may be
secondary to increased capillary blood flow and/ or increased permeability of the
blood-brain barrier. Individuals with a greater ratio of cranial cerebrospinal
fluid (CSF) to brain volume can more readily compensate for the swelling
through displacement of CSF3- 28.
The diagnosis of AMS is made clinically3, and the syndrome is dominated
by five major symptoms: headache, GI symptoms (nausea, vomiting, or
anorexia), dizziness and lightheadedness, fatigue, and difficulty sleeping.
Currently, the diagnosis of AMS is based on specific criteria, as defined by the
Lake Louise Consensus on AMS29. An individual's Lake Louise AMS Score is
calculated using a grading system in which the presence and severity of each of
the five symptoms described above is assigned a weight (see Table B). AMS is
defined as a headache and one or more additional symptom(s) in the setting of
recent ascent to altitude greater than 8000 ft (2500 m)29. Although decreased
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oxygen saturation (Sa02%) on pulse oximetry is often found, a low reading is
not required for diagnosis.
Symptoms typically develop 6 to 10 hours after ascent to an altitude of
2500 m (8000 ft) or higher. In rare circumstances, however, symptoms may
occur at as low as 6500 ft (2000m), or as early as 1 hour after exposure. Most
of the symptoms usually resolve within two to three days. Descent to lower
altitudes rapidly reverses the symptoms of AMS.
In a 1993 survey of 3,158 visitors to Colorado ski resorts, 18% of
individuals visiting altitudes of 6000-7000 ft reported symptoms indicative of
AMS. The percentages were slightly higher for those at higher elevations
—22%
at 7000-9000 ft (1850-2750 m) and 27% of those people visiting areas greater
than 9000 ft30. Forty to 50 percent of trekkers and climbers who reach an
altitude of 10,000-13,000 ft suffer from AMS3°-3:\ After rapid ascent to 13,000
ft (hours, as opposed to days), incidence of AMS increases to over 90%36. Other
studies have demonstrated similar prevalence; Montgomery (1989) studied
physicians attending medical meetings and found a prevalence of 25% under
9000 ft, and 40% at altitudes >9000 ft 31. A study of trekkers in Nepal reported
that 42% of those individuals traveling to altitudes higher than 14,000 ft
reported symptoms37. In Honigman's study (1993), headache was
overwhelmingly the most common symptom, affecting 54% of travelers
(although only 8% reported "severe" headache). This was followed by easy
fatigue (28%), shortness of breath (21%), dizziness (21%), loss of appetite (11%),
sleep disturbances (10%), and vomiting (3%)30.
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Table B. Lake Louise Acute Mountain Sickness Scoring System29
AMS= Altitude gain AND headache AND at least one other symptom AND a total






3 Severe headache (incapacitating)
2. Gastrointestinal symptoms:
0 No symptoms
1 Poor appetite or mild nausea
2 Moderate nausea or vomiting
3 Severe nausea and vomiting (incapacitating)
3. Fatigue and/ or weakness
0 Not tired or weak
1 Mild fatigue/weakness
2 Moderate fatigue/weakness
3 Severe fatigue/weakness (incapacitating)
4. Dizziness /lightheadedness
0 Not dizzy/ lightheaded
1 Mild dizziness /lightheadedness
2 Moderate dizziness/lightheadedness
3 Severe dizziness/lightheadedness (incapacitating)
5. Difficulty sleeping
0 Slept as well as usual
1 Did not sleep as well as usual
2 Woke many times, poor nights sleep
3 Could not sleep at all
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Patients with HACE, the end stage of acute mountain sickness, present 3
to 5 days after arrival at altitudes greater than 9000 ft (2750m). It is also a
clinical diagnosis and is characterized by AMS symptoms accompanied by
neurological symptoms, including mental status changes and truncal ataxia38.
Changes in consciousness may range from irrational behavior and lethargy to
global encephalopathy, obtundation and coma. Physical examination findings
may include ataxia, papilledema, retinal hemorrhages, and, rarely, focal
neurologic deficits (including cranial nerve palsies) secondary to elevated
intracranial pressure3. Importantly, in individuals with concomitant HAPE,
severe hypoxemia can result in a rapid progression from AMS to HACE over the
course of hours.
T2-weighted Magnetic Resonance Images of the brain typically reveal
reversible white matter vasogenic edema, most pronounced in the splenum of
the corpus callosum and centrum semiovale39 41. Computed Tomography
imaging may reveal nonspecific diffuse cerebral edema, although, typically, gray
matter is not involved39 (see Figure 2). Edema may be triggered through various
mediators, including endothelial release of vascular endothelial growth factor
























HIGH ALTITUDE PULMONARY EDEMA
High-altitude pulmonary edema (HAPE) is a form of non-cardiogenic
pulmonary edema. It is a life-threatening condition that can occur in
unacclimatized individuals who rapidly ascend to altitudes greater than 2500
m45. HAPE is commonly seen in climbers and skiers, and is responsible for the
greatest number of fatalities related to high-altitude illness3' 46. Individuals who
reside at high altitude may also develop HAPE after spending time at lower
altitude, a phenomenon termed reentry HAPE. As few as 2-3 days at low
altitude can render vulnerable individuals susceptible to developing altitude
illness upon re-ascent.
Although the overall incidence likely lies near 1-2%, incidence of high-
altitude pulmonary edema can vary greatly as a result of different ascent rates,
sleeping altitudes, and environmental conditions. A Peruvian study of 1 157
individuals ascending to 3782 m reported an incidence of 17% in children aged
13-17, and of 3% in individuals over 2 1 years of age47. A study of Swiss
climbers at 4559 m reported an incidence of 5.2%34. Subclinical HAPE is
thought to occur at a rate of six to ten times that of clinical HAPE
—
one study
demonstrated pulmonary rales in 23% of trekkers in Nepal, ofwhich only 4.5%
had clinical HAPE33.
The incidence of HAPE depends on multiple factors, including rate of
ascent, final altitude attained, sleeping altitude (elevation at which one sleeps),
duration at altitude, degree of physical exertion, ambient temperature48, sex,
age, altitude of permanent residence30, and individual susceptibility, including
prior history of high-altitude illness4951 and certain cardiopulmonary
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conditions52. Women appear to be slightly less likely than men to develop
HAPE30.33. 53.
Maximum altitude attained, sleeping altitude, and rate of ascent all serve
to influence the magnitude of hypoxic stress, thus increasing the incidence and
severity of high-altitude illness, including HAPE3. 51- 54. Incidence of HAPE
increases from 0.01% to 0. 1% at 8200 ft (2500 m) to 2-6% of individuals at
13,000 ft (4000 m)33. 34, 55-57. As in AMS, in an ascent to 18000 ft (5500 m)
occurring over hours rather than days, incidence increases six-fold, from 2.5%
to 15.5%55. 58. Residence above 3000 ft (900 m) and slow ascent rates are
associated both with a lower incidence and decreased severity of illness3' 30' 51> 54.
Physical fitness is not protective and vigorous physical exertion upon
arrival decreases one's ability to acclimatize30' 5961. This is thought to be
secondary to exaggerated hypoxemia, increased oxygen use and demand, and
increased pulmonary arterial pressures. Both temperature and exertion activate
the sympathetic nervous system, and are important contributors to disease
progression.
Previous history of high-altitude illness, demonstrating an intrinsic
susceptibility, is the most important predictor of recurrence; individuals who
have previously developed HAPE have a higher likelihood of a repeated
episode47. In a study of mountaineers with a history of exposure to high
altitudes, those with a history of radiographically documented HAPE had a 60%
incidence of developing HAPE upon subsequent exposure, whereas the
recurrence rate in their previously unaffected counterparts was only 10%55.
Susceptible individuals who ascend at a gradual rate (altitude gain of 300-350
m/day) as high at 7000 m have a significantly decreased risk of developing the
19
condition, highlighting the important interplay of extrinsic and intrinsic
factors55. Furthermore, even individuals with low susceptibility can develop
HAPE if they ascend too high, too quickly55.
A similar syndrome, subacute mountain sickness, or high-altitude
pulmonary hypertension, is seen in certain individuals who live at high
elevations. In this syndrome, persistent pulmonary hypertension leads to right
heart failure, and the accompanying clinical manifestations, including dyspnea,
edema, ascites, and hepatomegaly. The syndrome, often associated with
chronic mountain sickness (CMS), is seen in both infantile and adult
subtypes62.
Diagnosis
Patients typically present within 24 to 72 hours of arrival at high
altitude3. Early in the disease course, mild pulmonary edema may manifest as
dry cough and decreased exercise performance. However, progression to cough
productive of blood-tinged fluid, respiratory distress, and audible rales may
occur over a period of hours33. The rate of decompensation may be accelerated
by low ambient temperatures, physical exertion, and ascent.
The Lake Louise Consensus diagnostic definition of HAPE, as defined at
the 1991 International Hypoxia Symposium, includes at least two of the
following symptoms: dyspnea at rest, cough, chest tightness or congestion,
weakness or decreased exercise performance, in addition to at least two of the
following signs
—rales or wheezing audible in at least one lung field,
tachycardia, tachypnea, or central cyanosis38.









Chest X-ray reveals full pulmonary arteries and characteristic irregular
patchy infiltrates, typically seen in the right middle and lower lobes in mild
cases and progressing to diffuse, bilateral infiltrates in severe cases63 (see
Figure 3) . However, infiltrates tend to be localized to the mid-lung fields,
sparing the bases and apices. Findings differ from those typical of congestive
heart failure in that cardiomegaly, Kerley B lines, and the central "bat wing"
pattern are uncommonly seen in patients suffering from HAPE64. Computerized
tomography (CT) similarly demonstrates a patchy distribution of edema.
Patients with congenital structural cardiopulmonary anomalies that
restrict the pulmonary vascular bed and increase pulmonary vascular
resistance are at an increased risk for developing this condition3' 65. These
predisposing conditions include congenital unilateral absence of a pulmonary
artery365, mitral stenosis, and patent foramen ovale66. Multiple studies have
also demonstrated an increased susceptibility in individuals with Trisomy 2167.
21
Figure 3. Chest X-Ray of Patientwith High-Altitude Pulmonary Edema
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Pathophysiology
The result of a non-cardiogenic, non-inflammatory, hydrostatic leak,
high-altitude pulmonary edema is strongly associated with pulmonary
hypertension and elevated capillary pressures68. Increased pulmonary vascular
responsiveness to hypoxia, increased sympathetic output, decreased levels of
vasodilators, and inflammation have also be implicated in the formation of
edema fluid. Decreased ability to clear edema fluid further contributes to
alveolar fluid collection and flooding.
Neurohumoral and hemodynamic responses to hypoxia contribute to
non-uniform hypoxic pulmonary arteriolar vasoconstriction resulting in regional
overperfusion in areas of the lung demonstrating minimal vasoconstriction.
Hypoxia has been shown to cause more heterogeneous blood flow in HAPE-
susceptible individuals vs. non-susceptible controls 69.
The high pressure and flow created by this phenomenon results in
regional overperfusion, increased pulmonary capillary pressures, and results in
stress-induced damage and failure of the capillary wall70. Lung perfusion
scintography in individuals with HAPE demonstrate high perfusion in regions
with radiographic evidence of edema. Furthermore, broncheoalveolar lavage
demonstrates erythrocytes and high concentrations of high-molecular-weight
proteins in the edema fluid in the alveolar space, consistent with fluid leakage
resulting from increased capillary permeability71.
Animal studies in which pulmonary capillary pressures have been
increased to levels seen in HAPE have demonstrated almost complete disruption
of the capillary endothelial and alveolar epithelial layers of the wall72, possibly
secondary to distortion of the type IV basement membrane collagen matrix
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which composes the blood-gas barrier73. However, these stress-induced ultra-
structural changes are rapidly reversible within minutes
—
following a decrease
to normal pressures, approximately 70% of the disruptions in the capillary wall
appear to resolve74. This remarkable time course of resolution may hold the key
to the rapid clinical improvement seen with descent and /or supplemental
oxygen therapy.
Pulmonary hypertension is an important predisposing factor which plays
a role in the pathophysiologic mechanisms underlying HAPE. Cardiac
catheterization studies performed on patients with HAPE have uniformly
demonstrated pulmonary hypertension, increased pulmonary artery pressures
(PAP), and normal capillary wedge pressures6375. Pulmonary artery systolic
pressures in individuals with HAPE are as high as 144 mmHg, significantly
higher than the normal range of 60 to 80 mmHg76. In one study of nine HAPE-
susceptible and nine HAPE-resistant subjects exposed to acute hypoxia (12%
O2), pulmonary artery systolic pressure increased from 22 ± 3 to 33 ± 6 mmHg
in the HAPE-resistant subjects, whereas susceptible subjects' pressures
increased from 25 ± 4 to a significantly higher 50 ± 9 mmHg77. Susceptible
individuals also have abnormally high pulmonary artery pressures prior to the
onset of clinical HAPE78. In susceptible patients, prophylactic treatment with
nifedipine lowers pulmonary artery pressures and prevents HAPE78.
Isolated elevation of pulmonary artery pressure does not appear to be
sufficient to cause HAPE, however. Individuals with a history of perinatal
pulmonary artery hypertension caused by perinatal postpartum hemorrhage
display very high pulmonary artery pressures both at rest and following hypoxic
exposure. Despite these high PAPs, they do not demonstrate an increased
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likelihood of developing pulmonary edema when exposed to altitude79.
However, individuals with Down syndrome, who often have some degree of
pulmonary hypertension, have a significantly increased risk of developing
HAPE. In a study of 52 children with HAPE, six (12%) had Down syndrome67,
an incidence which is significantly higher than would be expected, given the
population frequency of Trisomy 21 (0.1%).
The expression of pulmonary hypertension results from a complex
interplay of genetic factors, immunologic responses, and environmental triggers.
Increased pulmonary vascular resistance in these settings may be the result of
either microvascular injury or obstruction of the pulmonary vasculature80.
Possible pathways include inflammation causing vascular injury, immune
complex deposition and vasculitis, and procoagulant activity-induced
vasculopathy (recurrent thromboembolism and/or thrombosis)80. The release of
cytokines and inflammatory mediators as well as vasoconstrictors, including
endothelin-181, may also contribute to the expression of pulmonary
hypertension, especially in the setting of hypoxia. Peripheral blood levels of
endothelin- 1
,
a potent pulmonary vasoconstrictor, increase with pulmonary
alveolar hypoxia82 and levels appear to parallel the time course of HAPE and the
accompanying pulmonary hypertension81.
Increased sympathetic activity in susceptible individuals may result in
increased vasoconstrictive response to hypoxia, thus resulting in increased
pulmonary pressures. In a study of 8 susceptible and 7 resistant
mountaineers, susceptible subjects demonstrated a 2 to 3 time greater
sympathetic nerve discharge in response to hypoxia than did their HAPE-
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resistant cohorts. Furthermore, sympathetic nerve activity was directly
correlated with pulmonary artery pressures83.
In HAPE-resistant individuals, slightly increased pulmonary arterial wall
pressures may actually serve to induce vascular remodeling via increased
synthesis of collagen and elastin and growth factors. This remodeling begins
within hours of the application of moderate tension to pulmonary artery
segments in vitro4, and may demonstrate the mechanism by which the
capillaries may be somewhat protected from the increased upstream pulmonary
pressures.
Individuals susceptible to HAPE demonstrate an exaggerated hypoxic
pulmonary vascular response (HPVR) to both brief and prolonged exposure to
hypoxic conditions21. 84> 85, resulting in an excessive rise in pulmonary artery
pressure (PAP). This response, a vestigial reflex important in fetal life, is
responsible for shunting blood away from the fetal lungs. In healthy adults,
this vasoconstrictive response functions to reduce arterial hypoxemia by
diverting blood flow from poorly oxygenated areas, thus preventing ventilation-
perfusion (V/Q) mismatch. However, in the setting of systemic hypoxia, as seen
with ascent to altitude, this compensatory response can become maladaptive.
In individuals with long-term exposures to hypoxic hypoxia, persistent
excessive pulmonary vasoconstriction may result in the development of high-
altitude pulmonary hypertension and right heart failure. Conversely,
individuals who are well adapted to the hypoxia of high altitude display a very
weak HPVR. The same holds true in animals adapted to live at high altitudes,
including Tibetan sheep and yak86.
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HAPE- susceptible children develop greater pulmonary arterial pressures
than do their non-susceptible counterparts during an acute hypoxic
challenge87. This excessive vascular response may be due to relative
hypoventilation, as these individuals have been shown to have a poor
ventilatory response to hypoxia (HVR)2°. 2i,88; resulting in decreased alveolar P02
and arterial oxygenation, both stimuli for HPVR. However, whether this
response results from an exaggerated response to hypoxia, or is caused by more
severe hypoxemia is not known. During early exposure to hypoxia, prior to the
development of HAPE symptoms, arterial PO2 is lower in HAPE-susceptible
individuals than in their non-susceptible counterparts89. Why these individuals
develop such pronounced altitude-induced hypoxemia is still being
investigated68.
These individuals also demonstrate an abnormally vigorous increase in
pulmonary artery pressure combined with a decrease in arterial oxygen
saturation during normoxic exercise80' 84' 90' 91. This phenomenon likely
represents a constitutional hypersensitivity of the pulmonary circulation92. The
possible role of reduced peripheral chemoreceptor sensitivity to hypoxia in
exaggerated HPVR has been investigated in studies in which the carotid body
has been resected and/or denervated. These two interventions result in an
increased HPVR at any given alveolar P0293'
94
.
Hypoxia appears to impair endothelial function in susceptible individuals
secondary to either over-expression of vasoconstrictors (such as endothelin- 1 ,
angiotensin II, or arachadonic acid metabolites), or under-expression of
vasodilators (such as nitric oxide)95. Endothelial cells respond to the
hemodynamic and humoral changes resulting from hypoxia by producing
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vasoactive factors, including NO, which influence pulmonary artery smooth
muscle function. Generalized hypoxia-induced vascular endothelial
dysfunction results in decreased levels of NO production and decreased
vascular responsiveness.
Using venous occlusion plethysmography to assess vascular reactivity in
HAPE-susceptible and healthy controls under both normoxic and hypoxic
conditions, Berger, et. al. (2005) found that susceptible subjects had reduced
endothelium-dependent vasodilator responsiveness to an intra-arterial infusion
of acetylcholine77. Furthermore, an inverse correlation existed between the
vasodilator response to acetylcholine and pulmonary artery pressures. This
test, used to assess endothelial function, differentiates between intrinsic
endothelial dysfunction and deranged smooth-muscle function by examining
the differential vasoconstrictive responses to ACh and sodium nitroprusside
(SNP). The level of dysfunction found in HAPE-susceptible individuals was
comparable to that seen in hypertension and smoking77. Thus, in susceptible
individuals, hypoxia directly induces endothelial dysfunction, which is reflected
in an increased HPVR.
Endothelium derived nitric oxide (previously known as "endothelium-
derived relaxing factor") is one of the most potent vasodilators of the pulmonary
vascular bed and maintains pulmonary vascular tone in healthy individuals in
both normoxic and hypoxic conditions96. Inhaled nitric oxide (NO) reduces
hypoxic pulmonary vasoconstriction in both animals97 and humans96.
Conversely, the administration of NOS antagonists increases the
vasoconstrictive pulmonary response to hypoxia96. In hypoxic conditions, NOS-
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deficient transgenic mice have hyper-responsive pulmonary circulatory beds
and significantly higher PAPs than do their wild-type counterparts 98.
Decreased endogenous production and bioavailability of nitric oxide (NO)
has been implicated in the excessive hypoxic rise in PAP in HAPE-sensitive
individuals99. During a short hypoxic exposure at low altitude95, and during the
development of HAPE at high altitude100, HAPE-susceptible individuals were
found to have decreased exhaled nitric oxide concentrations, whereas
indigenous residents of both Tibet and the Andes exhale higher levels101.
Indeed, a negative correlation exists between exhaled NO and hypoxic
pulmonary vascular response (HPVR) 95> 10°.
Bronchoalveolar lavage performed on HAPE-susceptible mountaineers
after 2 days at 4,559 m demonstrated lower concentrations of nitrite and nitrate
in alveolar fluid, as compared to controls102. Additionally, HAPE-susceptible
individuals had decreased nitric oxide concentrations at 3500 m103, further
supporting the role of impaired NO production in the pathogenesis of HAPE.
Administration of a nitric oxide mixture (40 ppm, fraction of inspired
oxygen
=
20%) to subjects with HAPE resulted in improved gas exchange, a
large decrease in pulmonary arterial pressures, improved V/Q mismatch, and
improved arterial oxygen saturation104. 105. Similar results are seen with the
administration of vasodilators such as nifedipine and hydralazine106. These
findings support the hypothesis that, in HAPE-susceptible individuals, poor
endothelial responsiveness to decreased alveolar oxygenation results from
decreased NO availability, and an impaired NO-mediated vasodilatory response
contributes to decreased vascular responsiveness.
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The use of the phosphodiesterase-5 inhibitors sildenafil and tadalafil,
which inhibit the degradation of nitric oxide's second messenger, cyclic
guanosine monophosphate (cGMP), exploit this pathway to treat HAPE. These
agents have been shown to reduce hypoxic pulmonary vasoconstriction, lower
PAP107, improve exercise capacity io8,io9> ancj reduce the occurrence of HAPE at
high altitude 110.
A small body of evidence also supports the use of dexamethasone for
treatment of high-altitude pulmonary edema. The administration of 16mg of
dexamethasone per day for 2 days preceding ascent was as effective in
prevention, and lowered PAP as much as tadalafil110. The proposed pathway
involves the nontranscriptional activation of endothelial NO synthase (eNOS)111
in addition to increasing eNOS expression in vitro112. Mice treated with
dexamethasone demonstrated decreased vascular permeability,113 independent
of PAP. Dexamethasone has been used with varying rates of success, however.
Polymorphisms in glucocorticoid receptors responsible for differential activation
of the associated metabolic and cardiovascular pathways involved in HAPE may
account for this variability92' 114.
Inflammatory processes, including the release of inflammatory mediators
in response to hydrostatic injury, may also play a role in HAPE115 117. Though
inflammatory markers are not seen in early stages102 they are present in
alveolar fluid later on in the progression of the disease118. Bronchoalveolar
lavage of subjects at 4400 m has demonstrated increased levels of
polymorphonuclear leukocytes (PMNs), protein, leukotriene B4, and complement
factor 5a (C5a) in the airways119. Further studies of edema fluid have
demonstrated increased levels of IL-1, IL-6, IL-8, and tumor necrosis factor-a,
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which may contribute to the development of pulmonary hypertension associated
with HAPE80. Elevated levels of IL-8 and increased PMN and protein
percentages resolved along with clinical symptoms in a case study of a
Japanese climber with severe HAPE 81. Increased levels of IL-8 and PMNs are
also seen in patients with ARDS, and are associated with poorer outcome120.
The release of inflammatory mediators may also play a role in the increased
vascular permeability seen in affected individuals.
It is possible that these inflammatory processes are triggered by an HLA
class II allele-mediated host response to an initial, inciting event or
environmental factor, such as an upper respiratory tract infection80' 87. The
inflammatory process may then lead to pulmonary hypertension in susceptible
individuals, and ultimately, clinical HAPE. Thus, constitutional susceptibility
results from a complex interaction between individual, immunologic, and
genetic factors. However, the absence of inflammatory cytokines during the
early phases of HAPE may suggest that the inflammation is secondary to the
vascular insult caused by increased pulmonary hydrostatic pressures.
There is an inter-individual variability in the ability to clear edema fluid
which has collected in the alveolar space
—
an imbalance between the secretion
and reabsorption of alveolar fluid predisposes to edema accumulation and
HAPE. The amiloride-sensitive sodium channel (ENaC), is responsible for 40-
60% of alveolar fluid clearance through the control of transepithelial fluid
transport in pulmonary alveolar epithelial (type II) cells102.
121-123 Mice lacking
the a-subunit (a-ENaC(-/-)) die shortly after birth due to an inability to clear
the lungs of alveolar fluid. However, ENaC(-/-) mice transfected with the ENaC
gene demonstrate moderate transport activity, sufficient for survival in
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normoxic conditions. When exposed to hypoxic conditions, however, these mice
have significantly more alveolar fluid, and recover more slowly than their
normal counterparts124.
Sartori et al. (1998) measured the potential difference across the nasal
epithelium in HAPE-susceptible climbers and controls. A surrogate marker for
alveolar epithelial concentration and sodium transport, the potential difference
was significantly lower in the susceptible climbers125. Decreased apical sodium
transport results in a diminished capacity to reabsorb alveolar fluid and
increased fluid accumulation and greater hypoxemia in HAPE-susceptible
individuals126.
Dexamethasone, a steroid being investigated for the treatment of HAPE,
enhances alveolar sodium and water reabsorption via upregulation of both
apical sodium channel and basolateral Na-K-ATPase activity127. Similarly, P2-
agonists both increase ENaC activity and enhance alveolar fluid clearance.
Treatment
First-line treatment involves increasing PIO2 through descent (and/ or
hyperbaric treatment, such as a chamber or Gamow bag) and supplemental
oxygen. Improved alveolar and arterial oxygenation functions to immediately
reduce pulmonary artery pressure by 30-50%106'
128' 129 in addition to decreasing
tachycardia and tachypnia64.
Descent of 500-1000 m (1600-3200 ft) provides the most rapid recovery.
However at times, often it is either impossible or undesirable. Patients typically
respond rapidly to supplemental oxygen. Treatment is initiated with a flow rate
of 4 to 6 L/min until clinical improvement, then titrated to 2 to 4 L/min to
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maintain Sa02 greater than 90%. If the patient does not descend, he or she
should receive outpatient continuous oxygen for 24 to 72 hours, with frequent
follow-up Sa02 monitoring64. 13°. However, those with severe HAPE, defined as
the failure of oxygen saturation to improve to greater than 90% within five-
minutes of the initiation of high-flow oxygen, and those with concomitant
HACE, should be transported to lower altitudes as soon as possible. Oxygen
treatment may be discontinued in the setting of clinical and radiographic
evidence of improvement. Cold stress and physical exertion also increase
pulmonary arterial pressure, and thus should be minimized as well.
Nifedipine, a calcium-channel blocker, is an effective supplemental
treatment modality. Although treatment does not affect oxygen saturation, it
reduces pulmonary- artery pressure by 30%106' 128.
Recently, selective type- 5 phosphodiesterase inhibitors such as sildenafil
and tadalafil have been used in the prevention and treatment of HAPE. In a
recent randomized, double-blind, placebo-controlled study, 7 of 9 patients
receiving placebo developed HAPE, while only one of 7 patients receiving
tadalafil became ill (p
=
0.007)110. In this study, the efficacy of tadalafil in
preventing HAPE was similar to that of nifedipine.
Inhaled beta-agonists, which function to increase clearance of fluid from
the alveolar space, and may lower pulmonary-artery pressure, may be used to
prevent HAPE in susceptible individuals131. Administration of salmeterol, a pV
agonist, reduced the incidence of HAPE by 50% in a group of susceptible
climbers121.
Because HAPE may be fatal, individuals with a demonstrated
susceptibility must take appropriate precautions before subsequent ascents to
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altitude. An ascent rate of less than 600 meters per day is suggested, physical
exertion should be minimized, and respiratory depressants should be avoided.
Additionally, acetazolamide (125mg by mouth, twice a day, starting 1-2 days
prior to ascent) is often used to assist in acclimatization.
GENETIC FACTORS INFLUENCING SUSCEPTIBILITY
It is currently not known why only a small number of individuals
exposed to high-altitude go on to develop HAPE though it is understood that
individual susceptibility to develop altitude-related illness varies substantially.
It is clear that both environmental and individual, genetic factors play
important roles in the development of the syndrome.
A number of studies have strived to identify the genetic variants which
contribute to, and characterize the physiology of, individuals predisposed to
HAPE and other altitude-related illnesses. These include both epidemiological
studies and genetic /molecular evidence for genetic contributors to
susceptibility. The epidemiologic evidence includes family clustering,
population patterns, and individual susceptibility.
Genetics of the Hypoxic Ventilatory Response
As discussed previously, the ventilatory response to hypoxia plays an
important role in susceptibility to altitude illness, specifically HAPE. Multiple
studies provide evidence for the influence of familial and genetic factors on
hypoxic ventilatory response (HVR)132135. There is considerable inter-individual
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variation in the magnitude of ventilatory response to hypoxic stress. Hirshman
et al. (1975) demonstrated a wide, bimodal, distribution of HVR, suggesting the
variance may be influenced by underlying genetic determinants134. The
magnitude of ventilatory acclimatization is not significantly correlated with age
or gender 136. When compared to their untrained counterparts, athletes with a
high V02 max have been found to have a markedly diminished HVR137. 138.
Relatives of children with unexplained respiratory failure have also shown
markedly depressed HVR 13« 14°. Scoggin et al. (1978), described familial
clustering of low HVR in families of endurance athletes138. Additionally, twin
studies have shown a greater concordance between monozygotic than dizygotic
twins132, strongly suggesting that genetic determinants influence ventilatory
response to hypoxia.
Magnitude of ventilatory response to hypoxic stress differs amongst
ethnic groups residing at both high and low altitude, further suggesting an
intrinsic influence133. 141. Tibetans exhibit a ventilatory response almost double
that of the Bolivian Aymara living at the same altitude141. The Himalayan
Tibetans also have higher resting ventilation, greater arterial oxygen saturation,
and less polycythemia than the Aymara. The proportion of HVR variance
attributable to heritable determinants was significant in both cases.
Genetic determination of HVR is also supported by inter-species variation
in ventilatory response. The bar headed goose, which is exposed to extreme
high altitude as it migrates over the Himalayas, exhibits a diminished
ventilatory response to hypoxic stress, which resembles the phenomenon of
hypoxic desensitization in humans142. Those members of the species who were
born and raised at low altitude show a similar response, suggesting this
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response is mediated by a heritable mechanism, rather than by adaptation to
chronic exposure.
Tankersley (2001) developed a model in which in-bred strains of mice
exhibited different magnitudes and patterns of ventilatory responses to acute
hypoxic challenge. Furthermore, linkage analysis demonstrated that a
substantial proportion of the variance could be attributed to a genetic locus on
mouse chromosome 9 143. Further evidence that genetic modulation influences
responsiveness of the carotid body to hypoxia is found in a study by Weil et al.
(1998), which demonstrates that rat strains with a diminished HVR also display
decreased activity of the carotid sinus nerve in hypoxic conditions144. The
excised carotid bodies from the poor responder strains showed decreased
intracellular calcium concentrations in response to hypoxia.
Tyrosine hydroxylase is a rate-limiting enzyme in the carotid body which
influences the rate of synthesis of dopamine, and may play an important role in
inter-individual variation in ventilatory response to hypoxia. Because the
ability to mount an adequate hypoxic ventilatory response is protective against
the development of AMS and HAPE, it has been hypothesized that the rate of
production of dopamine, a catecholammergic neurotransmitter which functions
as a respiratory stimulant, may be associated with susceptibility. A study of
forty-three Japanese subjects with a history of HAPE, and fifty-one health
controls, found no association between two polymorphisms of this gene and
blunted HVR or HAPE susceptibility145. The carotid body's role in the regulation




Epidemiological reports of particularly susceptible individuals and
families have been cited as evidence that these individuals have an innate
predisposition to become ill at altitude14614^
History of AMS was the most reliable predictor of illness in a study of 847
mountaineers climbing to the 4559 m Capanna Margherita. Those with a
history of illness were two to three times more likely to become ill than were
those individuals who had not previously experienced difficulties at high
altitudes51. A large study of visitors to ski resorts in Colorado identified
previous history of illness as the second strongest predictor of illness (after
altitude of permanent residence)30. Furthermore, a study of astronomers at the
4200 m Mauna Kea observatory demonstrated that susceptible individuals not
only suffered repeated bouts of AMS, but that illness severity was consistent
and reproducible150.
Similarly, a previous history of HAPE is the strongest predictor of the
likelihood of recurrence upon exposure to high altitude. In individuals who had
previously climbed above 3000 m, 66% with a history of HAPE developed
clinical symptoms, as opposed to only 12.5% of those with no history151. In
another study at 4560 m, 64% (7 of 1 1) of individuals with a history of HAPE
became ill78.
The genetic underpinnings of susceptibility are supported by cases of
apparent familial clustering of increased susceptibility. These reports, which
suggest that the disease is seen
in higher frequencies within certain families
than in the general population, support the concept that important inherited
traits are shared and transmitted within families.
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Norboo et al. described a family of four who ascended to 3000 m, of
which three members developed HAPE149. Hultgren has also described several
cases of apparent familial clustering. One of these cases involved a Peruvian
family, in which the eldest daughter developed HAPE multiple times; her two
sisters also became ill under similar conditions146. In another family described
in the same study, two brothers developed HAPE after traveling from sea level to
3700 m. In 1962, Fred et al. described a family in which a young man suffered
several episodes of severe HAPE while hiking at moderate altitudes. His father
had died following the development of severe dyspnea and weakness while
hiking in the Andes at a similar elevation147.
In a twin study of 17 pairs of young children, 6 of the 7 children who
developed AMS were sibling pairs (two sets ofmonozygous twins, one set of
dizygous)152. As previously discussed, twin studies have also shown that
ventilatory response to hypoxia is influenced by genetic factors132' 153.
Epidemiological studies of population patterns of susceptibility have
demonstrated promising results. Many studies have found differential
adaptation patterns in indigenous residents of high altitudes in the Tibetan
Himalaya and those from the South American Andes. Furthermore, differences
between populations with long histories of high altitude residence and
populations which have more recently emigrated suggest that evolutionary
pressures have resulted in genetic selection for traits which improve
acclimatization.
Chronic mountain sickness (CMS) is seen more frequently in indigenous
Andeans than in their Tibetan counterparts154, suggesting differential
adaptation between the two populations. As compared to the Han Chinese, who
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have only recently immigrated to the Tibetan highlands, Tibetan natives have a
much lower incidence of high altitude pulmonary hypertension (HAPH)155. The
musculature of the pulmonary vascular system (especially the small pulmonary
arteries) of the indigenous Tibetans is less robust than in the Han Chinese156,
and likely contributes to lower pulmonary artery pressures in this population,
thus affording the natives relative protection against HAPH. Other animals well
adapted to high altitudes, including Yaks, also demonstrate a relative paucity of
smooth muscle in the pulmonary vasculature.
Genetics of HAPE
Genetic and molecular studies have identified numerous genes which
may play an important role in altitude adaptation and acclimatization. Because
altitude-related illness are, by definition, dependent on environmental
conditions, and thus, the syndrome must result from gene-environment
interactions, it is difficult to identify the exact role each of these genes plays in
the ultimate illness.
Most of the research has consisted of gene association studies, which
look to identify genes in which certain alleles are statistically overrepresented
(or underrepresented) in HAPE-susceptible individuals. Polymorphisms,
whether in the coding sequence or regulatory regions, may alter the structure
or quantity of the gene phenotype, thus influencing the body's ability to adapt
to the hypoxic stress of high-altitude.
A Japanese study of 30 HAPE-susceptible individuals and 100 healthy
controls demonstrated a significantly increased frequency of HLA class II alleles
-DR6 (46.7% vs. 16%) and -DQ4 (40% vs. 10%) within the major
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histocompatibility complex of susceptible individuals. All eight subjects who
were positive for either HLA-DR6 or HLA-DR4 had histories of recurrent HAPE.
In the same study, cardiac catheterization demonstrated increased pulmonary
arterial pressures in those expressing the HLA-DR6 allele80. These results
suggest that pulmonary hypertension may be related to the HLA-DR6 allele,
which is also associated with primary pulmonary hypertension in HIV157. The
presence of HLA-DR6 is also associated with an increased risk ofmortality in
scleroderma158.
Polymorphisms in the angiotensin-converting enzyme (ACE) and
endothelin-1 (ET-1) genes, both important in maintaining vascular tone, have
been associated with an increased susceptibility to HAPE. ACE is intimately
involved in fluid balance (via aldosterone), the production of angiotensin-2 (AT-
2), a vasoconstrictor, and the degradation of bradykinin, a vasodilator.
Following exposure to a hypoxic stimulus, ACE levels decrease in all subjects,
though a greater drop is seen in association with more successful
acclimatization159. The two major alleles include the ACE-D (deletion) and ACE-
I (insertion) alleles; ACE-I as associated with lower baseline circulating ACE
concentrations, and is more commonly found in individuals who perform well at
altitude160, whereas ACE-D is overrepresented in HAPE-susceptible
populations161' 162. Charu et al (2006) and Tsianos et al. (2005) have reported
an association between the I/D genotype and increased susceptibility to HAPE
and AMS163.
However, the ACE-I allele, which is generally associated with better
performance at altitude, is found more commonly in indigenous residents with
high-altitude pulmonary hypertension164. This may suggest that the ACE-I
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allele is more influential during the more acute time course associated with
HAPE, as opposed to the long-term maladaption resulting in HAPH.
Elevated levels of endothelin- 1 (ET-1), another vasoactive peptide and
regulator of blood pressure, are seen in both pulmonary hypertension and
HAPE165. Hypoxia acts as an important stimulus for increased production of
ET- 1
,
which binds receptors on fibroblasts and pulmonary vascular smooth
muscle cells 166, inducing smooth muscle cell proliferation and vasoconstriction
167. Plasma ET-1 levels are inversely related to oxygen saturation and inversely
correlated with pulmonary artery pressures168
The endothelia of the vasculature produce endothelial nitric oxide
synthase (eNOS, or NOS3) which synthesizes nitric oxide from the amino acid L-
arginine. As discussed above, nitric oxide is a potent vasodilator which plays
an important role in the maintenance of pulmonary vascular tone. As such,
lower NO levels are associated with an increased susceptibility of HAPE95.
A study of 60 HAPE-resistant and 72 HAPE-susceptible patients found
an overrepresentation of specific eNOS polymorphisms, including the NOS3
heterozygote genotype combinations GTba and GTbaAGTC, in HAPE sufferers.
These polymorphisms are also correlated with decreased NO concentrations103.
An association between two eNOS a/b polymorphisms, the 4a and the
T894 alleles, with Glu298Asp and HAPE susceptibility were demonstrated in a
Japanese study169. These specific polymorphisms are also associated with
essential hypertension and coronary artery disease169. The 4a allele is
associated with lower exhaled concentrations of NO170- 171.
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Genetics of the Hypoxic Response
While most of the HAPE-specific genetic research has consisted of gene
association studies of gene polymorphisms, a large amount of basic science
research has focused on genes that are responsible for general physiological
adaptation to hypoxia and the effect of hypoxia at a molecular level.
The importance of molecular responses to hypoxic adaptation is
demonstrated by hypoxia inducible factor- 1 (HIF-1), a protein complex which
acts as the "master regulator" ofmolecular response to cellular hypoxia172. This
powerful gene influences the expression of as many as 5% of human genes,
including erythropoietin and tyrosine hydroxylase.
HIF binds to hypoxia response elements (HREs) , transcriptional
activation sequences found in a broad variety of genes. When inserted in a
gene's promoter sequence, HRE confers hypoxia sensitivity173. Thus, genes
with the HRE enhancer element display hypoxia-dependent gene expression.
HREs are found in many of the genes discussed previously, including NOS,
endothelin, VEGF, tyrosine hydroxylase and erythropoietin. It is known that
mutations in the HRE can result in a decreased sensitivity to hypoxia, and
disruption in the function of this transcriptional activator may cause decreased
enzyme and protein function.
Binding of the HRE to HIF- 1 promotes transcription of "hypoxia-
sensitive" genes. The active protein complex consists of two subunits, HIF- la
and HIF- 1(3, which bind together to activate transcription. Concentrations of
HIF- la are actively down- regulated under normoxic conditions, as molecular
oxygen is a necessary substrate for its degradation. In hypoxic environments,
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however, the subunits translocate to the nucleus, where they bind to HREs of
hypoxia-regulated genes.
Other proteins which function to down regulate HIF- la activity include
the von Hippel-Lindau protein (pVHL), factor-inhibiting HIF- la (FIH-1), and E3
ubiquitin ligase. Disruption in the function of any of these proteins may
contribute to HAPE susceptibility.
Polymorphisms within these important genes and pathways may
contribute to inter-individual differences in responses to hypoxia, and thus,
susceptibility to high-altitude illness164'
174
through alterations in the structure
or quantity of affected genes.
SUMMARY
High-altitude pulmonary edema is an unpredictable and potentially fatal
condition which affects previously healthy individuals ascending to high
altitudes. However, at this time, it is not possible to predict who will become ill
upon exposure to hypoxia. Individuals who have suffered from HAPE have
significantly higher rates of recurrence, an important observation that suggests
the etiology is influenced by underlying constitutional or genetic components.
Much recent research has focused on describing the specific genes and
molecular and cellular pathways involved in physiological adaptation to
hypoxia. Numerous studies have shown that polymorphisms in these genes are
correlated with both individual physiologic responses to hypoxia and
susceptibility to altitude-related illness. Further research focused on the genes
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that are responsive to hypoxia may lead to a better understanding of the genetic
underpinnings of this syndrome.
The physiologic responses to prolonged hypoxia involve changes in gene
expression mediated by transcription factors. It has been shown that hypoxia
directly influences genes which encode mediators of diverse pathways including
carotid body sensitivity, pulmonary vascular remodeling, and production of
catecholamines and erythropoietin175.
As such, an increased understanding of the biochemical pathways
involved in the physiological response to hypoxia is necessary to gain insight
into the pathogenesis of HAPE. Further delineation of these pathways may also
allow for the development of reliable diagnostic markers which may be used to
predict who will become ill upon exposure to high altitudes. It is important to
note, however, that differences in gene expression and activity can demonstrate
only correlation, not causality.
It has been shown that systemic diseases affect the cytokine and
chemokine milieu of circulating peripheral blood cells176. These changes include
alterations in growth factors such as vascular endothelial growth factor (VEGF),
nitric oxide, prostacyclin, and endothelin. Peripheral blood cells are
continuously exposed to this altered cytokine environment, thus resulting in
differential gene expression patterns in PBMCs (peripheral blood mononuclear
cells) in different patient populations. Geraci et al. (2001) recently completed a
microarray study using a PBMC protocol, in which PBMCs in 16 patients with
primary and secondary pulmonary hypertension demonstrated differential gene
expression patterns176. From this, they generated an "expression signature" of
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72 genes which are differentially expressed in classes of pulmonary
hypertension.
Though molecular profiling using microarray analysis has traditionally
only been performed on tissue samples, surrogate markers, including PBMCs
may be used for gene expression profiling. In fact, numerous studies, including
Geraci's, have used peripheral blood cells to describe differences in gene
expression in a variety of disease states177.
HYPOTHESIS AND SPECIFIC AIMS
Multiple modulating genes and environmental factors are implicated the
development of high-altitude pulmonary edema. However, the exact nature of
these gene-environment interactions remains unclear, and has not been
described. The study of gene expression patterns in the form of microarray
analysis allows for the measurement of the expression of thousands of genes,
and can be used to identify differences in gene expression in HAPE-susceptible
individuals and those who do not develop the condition. Microarray has
recently been used to identify differential gene expression in disease states
including AML (acute myelogenous leukemia), lupus, multiple sclerosis, sickle
cell anemia, and pulmonary hypertension177. It has also been used to uncover
the mechanisms underlying many pulmonary diseases, including asthma,
pulmonary fibrosis, and pulmonary hypertension 178. However, this is the first
study of its' kind on patients with HAPE. The goal of the present study is to
characterize the relationship between gene expression and HAPE susceptibility.
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There are many unanswered questions which lend themselves to further
research regarding the genetic modulation of hypoxic response and
acclimatization. These include elucidation of the mechanism of action of these
genetic modulators, as they may influence peripheral chemoreceptors, central
mechanisms, or modulate other inflammatory or immunologic pathways.
At this time, there is no reliable method to predict those individuals who
might become ill upon exposure to high altitudes. Recent results suggesting
that HAPE susceptibility is associated with specific genotype combinations
support the idea that, in the future, genetic markers may be useful for
predicting the risk of HAPE103. By describing the mechanisms by which
humans adapt to the hypoxic stress of high altitude, we may also gain insight
into the pathogenesis of other chronic hypoxic states, including respiratory
failure, COPD, and cyanotic heart disease1.
The purpose of this study is to further investigate the genetic
contributors which influence constitutional susceptibility to high-altitude
pulmonary edema. By performing a genome-wide analysis of gene expression
patterns in both individuals suffering from HAPE and in healthy controls, it will
be possible to investigate the contribution of various genes of interest.
Furthermore, this study aims to assess the contribution of genes which may
not have previously been identified and/ or investigated in the pathogenesis of
the syndrome.
This study seeks to determine whether the gene expression profile in
patients diagnosed with high-altitude pulmonary edema differs from those
without HAPE. It is hypothesized that microarray analysis will reveal distinct
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differences in PBMC gene expression profiles between individuals with HAPE
and control subjects who did not develop HAPE upon exposure to high-altitude.
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METHODS
The study protocol was approved by the Colorado Multiple Institution
Review Board (COMIRB), protocol number 05-1034.
CONSENT PROCEDURES
HAPE patients and controls presenting to the Telluride Medical Center
were informed about the study by their treating physician. Written informed
consent was obtained, during which the study was explained and all questions
were answered. Participants were also asked to sign a HIPAA Authorization B
Form.
SUBJECTS
Patients presenting to the emergency room, urgent care clinic, and family
practice departments at the Telluride Mountain Clinic (TMC) between February
and April, 2006 were recruited.
Both individuals with HAPE and matched controls who met the
diagnostic criteria were asked to participate in the study. Eight subjects
presenting with High Altitude Pulmonary Edema (HAPE), as diagnosed by a
physician based on clinical findings and chest radiograph, were enrolled. There
were no recruitment restrictions regarding gender or ethnic background.
Patients' medical care was determined by the attending physician, and
included clinical examination, vital signs, and necessary diagnostic tests,
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including chest X-ray. Diagnostic criteria included a chest roentogram
suggestive of pulmonary edema (at least one quadrant of the lung, more than
50% ofwhich is affected by non-confluent infiltrate), the presence of hypoxemia
(O2 Saturation <90%) which unexplainable by other physiologic processes, and
the presence of rales, crackles, or frothy sputum on examination.
Exclusion criteria (see Table D) were chosen in order to exclude subjects
who may have other confounding causes of cardiogenic or non-cardiogenic
pulmonary edema. Patients were also excluded from the study if there was any
evidence of other active disease processes (unrelated to altitude illness).
Table D. Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Males and females between the ages of
18 and 70
Individuals with CHF or unstable
angina
Diagnosis of HAPE by Dr. Peter
Hackett, or attending physician at the
Telluride Medical Center.
Individuals with a history of
underlying lung disease, including
COPD, asthma, chronic bronchitis,
and restrictive lung disease
History of a systemic disease with








medications for prevention ofAMS or
HAPE, including acetazolamide and
dexamethasone .
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The control group was composed of 1 1 subjects who participated in a
hypobaric chamber study conducted by the Colorado Center for Altitude
Medicine and Physiology in Denver, CO. These subjects all had significant
previous exposure to altitudes to greater than 10,000 feet (a majority had a
history ofmultiple exposures to greater than 14,000 ft), and none had a history
of clinical HAPE. Peripheral blood was collected from these subjects following a
9-hour exposure to 16,000 ft in a hypobaric chamber.
Demographic data collected included gender, age, height, weight, and
ethnicity. Each subject's zip code at their place of permanent residence




HAPE+ subjects completed a questionnaire gathering information about
their symptoms upon presentation, ascent profile, and previous exposure to
altitudes greater than 8,000 ft (see Appendix A). Presence and severity of
dyspnea, cough, fatigue, and orthopnea were graded from 0 to 3 (no symptoms,
mild, moderate, and severe, respectively). Subjects provided information
including the timing and altitude at onset of symptoms and sleeping elevation
on night prior to onset. A careful ascent profile was obtained, including when
the subject left their place of permanent residence, when they arrived in
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Telluride, their method of travel, and maximum altitude attained over the prior
48 hours.
Information regarding any previous exposure to high altitude (>8,000 ft),
previous experience sleeping at high altitude, and prior history of AMS or HAPE
were also obtained. Each subject's degree of aerobic exercise at baseline and in
the previous 48 hours was graded as sedentary, moderately active, or very
active. Information about medications taken in the 48 hours previous to
diagnosis was obtained, with a specific focus on medications known to affect
acclimatization, including acetazolamide (Diamox, Sequels), NSAIDS, steroids
(i.e. dexamethasone), calcium-channel blockers (nifedipine), erectile dysfunction
drugs (sildenafil, vardenafil, tadalafil), nitric oxide, cold/flu/URI medications,
albuterol, oxygen and opioid agents (oxycodone, codeine, morphine,
hydromorphone) .
Relevant past medical history, family history, underlying medical
conditions, and history of pulmonary hypertension, congestive heart failure,
hypertension, unstable angina, underlying obstructive or restrictive lung
disease, systemic inflammatory diseases with known pulmonary
manifestations, and seizure disorders was also collected.
Subjects completed the Lake Louise acute mountain sickness
questionnaire29, which inquires about the presence or absence of 5 symptoms
in the 48 hours prior to presentation: headache, gastrointestinal symptoms,
fatigue and/or weakness, dizziness and/or lightheadedness, and difficulty
sleeping. Each symptom is graded on a 3-point scale, with "0" representing an
absence of the symptom, and 1, 2, and 3 representing mild, moderate, and
severe, respectively. The individual's Lake Louise AMS Score (LL-AMS), is the
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sum of the symptom scores. Mild AMS is defined as the presence of a headache
and one or more additional symptoms of mild severity, resulting in a total AMS
score of 2-4. Moderate to Severe AMS is defined as a headache in addition to
one or more additional symptoms of moderate to severe severity, or a total AMS
score of 5-15.
Sample Collection/ Isolation of PBMCs
Approximately 8mL of blood was drawn from each participant via a single
peripheral venipuncture, with a 21 -gauge needle. The blood was collected into
a BD Vacutainer CPT (cell preparation tube with 0.1 M sodium citrate
anticoagulant), and processed as per the manufacturer's instructions.
Specimens were processed within 2 hours of collection. The tubes are designed
to separate mononuclear cells (including monocytes/macrophages, B and T
lymphocytes, and natural killer cells) from other components ofwhole blood
using a cell separation medium composed of a density gradient liquid (Ficoll
Hypaque density fluid) and a thixotropic polyester gel barrier, thus forming a
stable separation medium between the cell layers. Density gradient
centrifugation isolated the relatively low density mononuclear layer and plasma
above the gel portion of the medium, which provided a stable separation from
the denser blood components (RBCs). Processing of 45 samples using the CPT
Tube Method resulted in an average recovery percentage 71.7% (SD=10.5), with
a total mononuclear cell purity of 98% (SD=1.8) (Data on File, Report No. R-88-
99-QC-195, BD Vacutainer Systems, NJ).
Following collection, blood was centrifuged in a Sorvall RT600
refrigerated centrifuge (DuPont) with a horizontal rotor (swing-out head) at 20 C
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for 20 minutes at 2700-3000 RPM. Following centrifugation, the mononuclear
cell layer was collected with a pipette and transferred to a 15mL conical
centrifuge tube. Phosphate buffered saline (PBS) was then added to bring the
total volume to 15mL. The cells were then centrifuged for 15 minutes at 1300-
1400 RPM. Following centrifugation, the supernatant was aspirated without
disturbing the cell pellet. The cell pellet was resuspended in lOmL PBS and
centrifuged again for 10 minutes at 1300-1400 RPM. The supernatant was
removed, and the cell pellet was suspended in ImL of RNALater (Ambion, inc.),
an aqueous storage reagent that stabilizes RNA and inactivates RNAses. The
product was then transferred to a cryotube and flash frozen at -80 C in liquid
nitrogen for long-term storage.
MICROARRAY ANALYSIS
The samples underwent sample preparation, total RNA isolation, high-
density oligonucleotide array hybridization and scanning in the University of
Colorado Microarray Core Lab using standard Core Lab procedures. The
Human Genome U133 Plus 2.0 GeneChip array from Affymetrix was used.
The "microarray cohort" was composed of 8 patients diagnosed with
high-altitude pulmonary edema and 1 1 controls with no history of HAPE,
despite previous significant altitude exposure.
RNA Isolation and Purification
Total RNA was isolated from the peripheral blood mononuclear cells
(PBMCs) using the RNAPrep kit from Agencourt Bioscience Corporation. The
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PBMCs previously suspended in RNAlater™ solution were centrifuged at 13,000
RPM for 5 minutes. The supernatant was carefully pipetted off without
disturbing the pellet layer. The PBMCs were resuspended in RNAPrep lysis
buffer containing SPRI paramagnetic beads, to which RNA and DNA bind.
Using a magnetic field, the total RNA and DNA were separated from the cell
lysate, washed with 70% ethanol, then treated with a DNAse I digestion
solution. RNA Bind Prep solution was then added to the digest to remove total
RNA. The supernatant was discarded, and the SPRI beads were washed with
RNAPrep Wash solution.
After separation in a magnetic field, the supernatant was discarded, and
the SPRI beads were washed 4 times with 70% ethanol. Total RNA was eluted
from the beads with 100 uL RNAse free water, and further purified using the
Qiagen RNeasy column from the RNeasy MinElute Cleanup kit. RNA purity and
yield were determined using the NanoDrop spectrophotometer, and Agilent
Bioanalyzer.
High-density Oligonucleotide Array Hybridization and Scanning
Labeled cRNA probes were generated from total RNA samples using the
MessageAmp II-Biotin Enhanced Labeling Kit (Ambion). Reverse transcription
of 1.0 Mg of total RNA with a
T7 oligo- (dT) primer bearing a T7 promoter
sequence was followed by in vitro transcription
of the resulting DNA with T7
RNA polymerase to generate anti-sense
RNA copies of each mRNA. The quality
of total RNA and labeled cRNA were assessed with Agilent's Lab-on-a-Chip total
RNA nano-biosizing assay (Agilent Technologies, Palo Alto, CA).
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Biotinylated cRNA probes were hybridized to Affymetrix Human Genome
U133 Plus 2.0 chips. The chips were washed and stained using the Affymetrix
Fluidics Station 400 according to the manufacturer's standard protocol. The
chips were scanned using the Affymetrix GeneChip Scanner 3000 (Affymetrix,
Santa Clara, CA).
The image data (fluorescence intensities) on each microarray chip was
scaled to 500 target intensity and were quantified using the Microarray Suite
software (Affymetrix, Santa Clara, CA).
DATA ANALYSIS
Patient Demographics
Statistical analysis of the demographic data and dependent variables
that relate to the main hypothesis (arterial oxygen saturation, heart rate, etc.)
was performed using unpaired t-tests. Values are reported as mean ± standard
deviation. Differences were considered significant at p < 0.05.
Microarray statistical analysis
Protocols for data analysis of Affymetrix microarrays have been described
previously176.
Microarray output data was analyzed using the Partek genomics suite.
Filtering was performed to remove background noise. Genes whose expression
was not reliably detected (i.e., had an "absolute call" of "present" or "marginal")
in at least 50% were excluded. A two-sample t-test was then used to determine
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the degree to which the differential expression of genes in different cohorts was
greater than could be expected by chance.
Expression profiles of the HAPE group were compared to those of both
the AMS+ and the AMS- control groups. The data was corrected for multiple
hypothesis testing using the Bonferroni correction, a family-wise error rate
(FWER) control procedure. This multiple comparison correction reduces the
chance of false positives, or type I error.
KEGG Pathway Mapping and Gene Ontology Analysis
The Database for Annotation, Visualization, and Integrated Discovery
(DAVID; http://david.abccncifcrf.gov/tools.jsp) was used to characterize the
differentially regulated genes by functional categories. Functional annotation
clustering was performed on differentially expressed genes. Gene ontology
functional categories and pathways which were overrepresented based on co
occurrence of differentially expressed genes were identified. KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathways which were upregulated
were




The baseline clinical characteristics of the study subjects are displayed
in Tables E and F. The HAPE-susceptible subjects and control subjects (AMS+)
were similar in age (33 ±11.3 years, n
=
8, vs. 29 ± 4.9 years, n
= 11; p=0.279).
Six of the 8 HAPE subjects but only 3 of the 1 1 AMS+ subjects were male (p
<
0.05). The patients had similar body mass indexes (BMI) (26.5 ± 3.1, n
= 8, vs.
23.3 ± 2.5 years, n
= 1 1; p > 0.05).
All control subjects lived in the Denver metro area (average altitude=
5300 ft), whereas the average altitude of permanent residence for HAPE-
susceptible subjects was significantly lower (465 ± 437 ft; p
< 0.05). In the
AMS+ subjects, peripheral blood samples were drawn after 9 hours of exposure
to 16,000 ft, whereas the control subjects had spent a longer time (61.1
± 17.8
hours) at lower average altitudes (1 1,880 ± 734 ft; p
< 0.05).
The average arterial oxygen saturation
values were similar in the HAPE+
and AMS+ groups (73% ± 6.6 vs. 77.8%
± 7.9; p
=
0.21). However other vital
signs, including heart rate and respiratory rate,
differed between the cohorts.
The HAPE+ group had significantly higher heart rates (104
± 1 1. 1 vs. 91. 1 ±
9.9; p < 0.05) and respiratory rates (23
± 6.2 vs. 12.9 ± 3.9; p < 0.05). The
HAPE patients scored significantly higher on the Lake Louise scoring system
than did their AMS+ counterparts (9.5 ± 1.8 vs. 5.9 ± 1.7; p < 0.05).
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Table E. Characteristics of Subjects
Variable HAPE Control (AMS+) P- Value
(n=8) (n=ll)





BMI 26.5±3.1 23.3±2.5 0.025
HR (bpm) 104±11.1 0.016
RR (per min) 23±6.2 0.000
Arterial oxygen 75±8.4 77.7±7.9 0.211
saturation (%)a
Lake Louise acute- 9.5±1.8 5.9+1.7 0.000
mountain sickness
score
Maximum altitude 11880±734 16000±0 0.000
attained (ft)
Elevation of 465±437 5280 0.000
permanent
residence (ft)
Time at altitude 61.6±17.8 9±0.0 0.000
(hrs)
a
Oxygen saturation measurements taken at time of presentation for HAPE+,
and after 9 hours of exposure to 16,000 feet in AMS+ subjects.
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Table F. Characteristics of HAPE Subjects
ID Ag Sex Hear Res O2 LLS URI Altitude Prev Symptoms on presentation
t p Sat Sx of perm. Hx
Rate Rat (%) res. (ft)
(bpm) e
2 40 M 101 18 78 9 Y 0 N Shortness of breath while
walking on level ground,
chest tightness, "gurgly,"
pink sputum
3 46 M 100 20 78 6 N 0 Y Shortness of breath, "fluid
in lungs," bloody sputum,
low energy, severe
headache
4 27 M 116 22 71 11 N 580 N Severe shortness of
breath, headache,
malaise, cough
5 46 M 106 22 73 10 Y 600 Y Shortness of breath,
severe fatigue, cough
7 17 M 112 32 74 11 Y 1082 N Shortness of breath,
"couldn't catch breath,"
cough
9 20 F 110 18 74 8 N 366 Y Shortness of breath,
headache, productive
cough
10 29 F 80 21 59 10 N 63 N "Rattling in chest,'
coughing up yellow fluid,
fatigue, nausea
11 39 M 107 34 80 11 Y 1029 Y Shortness of breath, raspy
cough, headache
MICROARRAY ANALYSIS
The Human Genome U133 Plus 2.0 GeneChip® array from Affymetrix, a
single array consisting of 38,500 well-characterized human genes representing
the entire human genome, was used for gene expression analysis.
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Each gene on the GeneChip® is represented by 10 to 20 perfectly
matched (PM) and mismatched (MM) high-density oligonucleotide control
probes. The MM probe is identical to the PM probe, except at a central base,
and functions as a control. The intensity of the hybridization of a labeled
mRNA to these PM and MM "probe sets" is directly associated with the level of
expression of the gene.
Previous studies have shown that microarray is a reliable method for
determining gene expression patterns, and gives valid measurements of gene
expressions levels. Studies show a high correlation with "gold standard"
approaches to measurement of gene expression, such as quantitative real-time
PCR (QPCR)178.
3,248 genes had significantly different expression levels in the HAPE and
AMS+ cohorts (Bonferroni p < 0.05). When comparing HAPE vs. AMS-, 2,729
were differentially expressed (see Appendix B).
Genes thought to be involved in the pathogenesis of HAPE, including
those associated with hypoxic stress, vascular leak, and inflammation were
identified and included in the investigation for differentially expressed genes
with biological significance. These genes are listed in Table G.
Table G. Genes Previously Studied in HAPE
Gene
Endothelial nitric oxide synthase
Endothelin- 1
Endothelin receptor (ETA)






Neuronal PAS domain proteins











Angiotensin- 1 converting enzyme
Angiotensinogen gene polymorphism












Control of vascular tone NOS3
Control of vascular tone EDN1
Control of vascular tone
Angiogenesis VEGF









Control of gene transcription HRE























High-altitude pulmonary edema is a serious and potentially fatal
condition that affects previously healthy individuals who ascend to altitudes in
greater than 3000 m. Development of the syndrome results from complex gene-
environment interactions which have not yet been characterized. The relative
contribution of environmental factors, including hypoxia, hypobaria, and
ambient temperature, versus that of individual and genetic factors, such as
pulmonary hypertension and upper respiratory infections, is unknown.
Furthermore, biochemical mediators, including nitric oxide (NO) and
endothelin- 1 (ET-1), and the fluid balance regulators of the renin-angiotensin-
aldosterone system appear to play important roles in its pathogenesis. How
these mediators may be influenced by both genetic and environmental factors
has not been well described.
At the present time, there is an incomplete understanding of the
molecular mechanisms and pathways which underlie the development of high-
altitude pulmonary edema. What is known is that the pathogenesis of HAPE is
multi-factorial and occurs in relationship to multiple complex pathways,
including inflammatory processes and immunologic events. Oxygen sensing
mechanisms such as hypoxia-inducible factor- 1 (HIF-1), play a role in hypoxic
adaptation through the regulation of gene transcription, however, their role in
the acute physiologic response to hypoxic stress has not been well classified.
Presently, the early molecular events induced by hypoxia which result in
endothelial injury and edema accumulation remain elusive.
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Previous studies, focusing on genes known to be involved in physiological
adaptation to hypoxia, have attempted to identify the genetic basis of
constitutional susceptibility (or resistance) to altitude illness. These studies
have multiple limitations. While the overall body of evidence does support the
hypothesis that genetic contributors play an important role in susceptibility,
the small number of studies and small sample sizes limit the conclusions that
can be drawn at this time. Specific genes and pathways have been identified,
but they have not been fully explored, and the evidence is often inconsistent.
Furthermore, most research has focused on single mediators and molecular
processes. In this complex disease pattern, however, it is likely that the
underlying pathophysiology is influenced by the simultaneous activation of
multiple molecular pathways and mediators. Determining which factors and
pathways are relevant and how these environmental and genetic factors interact
with each other poses a significant challenge.
Microarray-based technology is a powerful tool which allows for genome-
wide measurements of gene expression. In our study, this allowed for
comprehensive analysis of expression profiles of both known genes and novel
gene products which may not have been previously associated with high-
altitude pulmonary edema. Using the global gene expression profiling afforded




This study has several limitations. As with any analysis of gene
expression patterns, differential gene expression and activity can only
demonstrate correlation, not causality. It is therefore difficult to determine
whether the differential expression is the cause, or result, of illness.
Furthermore, microarray measurements of gene expression levels are only
moderately correlated (r
=
0.5-0.6) with the expression levels of final protein
products 179. Thus, to definitively determine protein expression, protein levels
must be directly measured using a technique such as reverse transcription
polymerase chain reaction (RT-PCR)
The control groups represent another limitation. Because of limited
funding and sample contamination, the number of control subjects recruited at
the Telluride Mountain Clinic was insufficient. Therefore, a HAPE-resistant
cohort who participated in a hypobaric chamber study conducted by the
Colorado Center for Altitude Medicine and Physiology were used as controls.
None of these individuals had a history of high-altitude pulmonary edema,
despite significant previous histories of altitude exposure. The control subjects
were exposed to a more acute hypoxic stimulus than were the HAPE-susceptible
subjects, which may have influenced gene expression profiles.
MACROPHAGE GENE EXPRESSION IN HYPOXIA
Previous studies have demonstrated that gene expression occurs within
two hours of a stimulus such as hypoxia. In this study, therefore, exposure to
altitude should be a sufficient hypoxic stimulus for both groups to mount a
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response measurable in the form of a protein product. Those genes which are
differentially expressed may play an important role in the physiologic
mechanisms which result in the development of high-altitude pulmonary
edema.
Specific changes in macrophage gene expression have been
demonstrated to occur under hypoxic conditions. Hypoxia has previously been
shown to modulate macrophage function inflamed and diseased tissues in
which the blood supply is either insufficient or occluded 180. Macrophages are
present in all tissues and play an important role in inflammation, cell turnover,
and tissue remodeling; large numbers of monocytes accumulate in hypoxic
tissues and respond to the hypoxic stress by rapidly altering their gene
expression. This response occurs via up-regulation of HIF-1 and -2,
transcription factors which play an important role in physiological response to
hypoxia.
Hypoxia-regulated genes, including VEGF, fibroblast growth factor (FGF),
platelet-derived growth factor (PDGF), inducible NO synthase (iNOS) TNF-a, IL-
10, and PGE2, play important roles in angiogenesis, tissue revascularization,
and recruitment of inflammatory cells through the release of cytokines and
enzymes. In atherosclerosis, increased expression of CXCL8 (IL-8) acts as a
chemoattractant for T cells and increases proliferation and migration of smooth
muscle and endothelial cells in lesions180. Oxygen-regulated protein 150
(ORP150), also up-regulated in hypoxic conditions, may influence macrophage
survival through suppression of hypoxia-induced apoptotic cell death181.
Studies of gene expression patterns in tumors, atherosclerosis, wounds, and
bacterial infections have demonstrated a significant overlap in the pattern of
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gene expression by hypoxic macrophages in different disease states. The
"hypoxic phenotype" is characterized by upregulation of HIF- 1 and induction of
proinflammatory and proangiogenic genes.
GENES EXPRESSED IN PULMONARY HYPERTENSION: RhoA AND Rho-
KINASE
The importance of RhoA and Rho kinase (ROCK) in vascular tone,
vascular remodeling, and pulmonary hypertension have been demonstrated in
various animal and human studies182. RhoA, a small GTPase protein,
contributes to vasoconstriction through downstream inhibition ofmyosin light
chain phosphatase through increased Ca2+ sensitivity of vascular smooth
muscle cells. The accumulation of phosphorylated MLC results in increased
vascular tone and vasoconstriction. This pathway is also influential in
regulation of vascular remodeling, cell migration, and gene expression,
suggesting that the Rho signaling pathway may be implicated in various
pulmonary vascular disorders183.
Rho-kinase, a downstream target of RhoA, has been implicated in the
pathophysiology of several diseases resulting from enhanced smooth muscle
vasoconstriction, including hypertension and coronary artery spasm 184.
Rho/ROCK is highly activated under conditions of inflammation and injury,
and activation of the pathway by inflammatory stimuli results in the
upregulation of cytokines and inflammatory cells that further increase
inflammation (see Figure 4). Rho signaling is activated by vasoconstrictors
including endothelin- 1 , thromboxane A2, angiotensin II, and serotonin, which
are thought to be involved in the pathogenesis of HAPE.
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Furthermore, activation of Rho-kinase downregulates endothelial nitric
oxide synthase (eNOS) expression18^ an important mediator in pulmonary
vascular tone. As discussed previously, decreased levels of endothelial nitric
oxide synthase are implicated in pulmonary hypertension and HAPE.
Figure 4. Role of Rho-KinaseMediated Pathway in Vascular Smooth Muscle
Contraction184
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The fawn-hooded rat (FHR), a genetic strain that develops severe
pulmonary hypertension when raised in the mild hypoxia of Denver (altitude of
5,280 ft), demonstrates increased levels of RhoA activity and Rho-kinase I
protein expression in the pulmonary arteries. Administration of the selective
Rho-kinase inhibitor, Fasudil, resulted in a selective reduction of pulmonary
artery pressures in these rats182.
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Fasudil has also been demonstrated to reduce pulmonary vascular
pressures in human subjects with pulmonary arterial hypertension (PAH)185.
Following the intravenous administration of 30mg of Fasudil over 30 minutes in
8 patients with PAH, mean pulmonary artery pressure decreased from 41.3 ±
12.8 mmHg to 37.9 ± 14.6 mmHg (p < 0.05). Pa02 was not decreased in these
patients.
Fasudil was first used in Japan for the prevention of cerebral vasospasm
in patients with sub-arachnoid hemorrhage, and the intravenous formulation
received Japanese approval in 1995. The drug is currently in phase II clinical




Multiple Rho-related genes were strongly expressed in patients with
HAPE (see Table H). Specifically, gene expression of Rho-kinase (ROCK) was






MADS box transcription enhancing factor 2, polypeptide A (also referred
to as myocyte enhancing factor 2A; MEF2A), an important transcriptional
regulator which operates upstream of eNOS and thrombomodulin in endothelial
cells, is also differentially expressed in HAPE.
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Table H. Rho- and Rho-kinase Associated Genes Differentially Expressed in
HAPE (vs. AMS)
Gene Name Gene Symbol p-Value
Rho-associated, coiled-coil containing protein
kinase 1
ROCK1 1.37E-03
Rho GTPase activating protein 5 ARHGAP5 7.01E-08
Rho GTPase activating protein 15 ARHGAP 15 3.16E-11
Rho GTPase activating protein 26 ARHGAP 26 1.41E-02
Rho guanine nucleotide exchange factor (GEF)
3
ARHGEF3 1.77E-07
Rho guanine nucleotide exchange factor (GEF)
7
ARHGEF7 1.39E-04
Myosin phosphatase-Rho interacting protein M-RIP 1.51E-03
Kruppel-like factor 3 (basic) KLF3 9.57E-04
Kruppel-like factor 7 KLF7 3.45E-06
Kruppel-like factor 8 KLF8 3.03E-03
Kruppel-like factor 12 KLF12 9.52E-07
MADS box transcription enhancer factor 2,
polypeptide A (Myocyte enhancer factor 2A)
MEF2A 7.65E-03
MADS box transcription enhancer factor 2,
polypeptide C (Myocyte enhancer factor 2C)
MEF2C 7.71E-08
MADS box transcription enhancer factor 2,
polypeptide D (Myocyte enhancer factor 2D)
MEF2D 5.31E-03
GENE EXPRESSION IN ARDS AND HAPE
Acute respiratory distress syndrome (ARDS) is the most severe form of
acute lung injury (ALI), a devastating illness which is often associated with
sepsis, trauma, and mechanical ventilation. The syndrome is characterized by
edema formation, bilateral infiltrates, severe hypoxemia, respiratory failure, and
can lead to multi-organ failure and death187. Much like HAPE, the pathogenesis
is linked to inflammatory processes, endothelial injury, and vascular leak, and
is thought to result from a complex interaction of environmental and genetic
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factors. Disease progression and recovery varies widely, and a large body of
research has focused on the genetic variations which may underlie
susceptibility to ARDS.
The heat shock proteins (HSPs) represent a highly conserved biological
response to stress. Exposure to a stimulus results in a rapid induction of the
genes encoding heat shock proteins, which serve as molecular chaperones
during protein synthesis, assembly, and transport. Thus, by maintaining the
conformational integrity of intracellular proteins, HSPs induce stress tolerance
and protect cells from further damage. HSPs also function to inhibit
inflammatory cytokine production188. The HSP70 family (70kDa) which
includes HSP70-2 (also called HSPA1B) and HSP70-Hom (also called HSPA1L),
is the most well-described and best-studied, though a 90kd form also exists.
HSPA8 (HSP70 kDa, protein 8), was found to be up-regulated in a number of
studies of gene expression in ventilator-induced lung injury (VILI)178. iss.is^
suggesting that HSP70-related genes may be important to the pathophysiology
of ALI and VILI. Furthermore, in a group of animals exposed to endotoxin-
induced ALI followed by ventilation, a significant inverse correlation was
demonstrated between HSP70 expression and inflammatory cytokines including
interleukin 1 (IL-1(3), interleukin 6 (IL-6), and tumor necrosis factor (TNF-a)190,
further supporting the anti-inflammatory role of HSP70.
In this study, none of the members of the HSP70 family were
differentially expressed in HAPE. Because the heat shock proteins are a highly
conserved biological process across organisms, and are characterized by rapid
induction in response to environmental stress, it is likely that all subjects
exposed to the hypoxic stress of high-altitude demonstrated a vigorous HSP
70
response. However, HAPE-susceptible subjects differentially expressed two
members of the HSP 90 kDa family: heat shock protein 90 kDa alpha
(cytosolic), class B member 1 (HSP90AB1) and heat shock protein 90 kDa beta




4.32x103). Both of these
proteins function as molecular chaperones of the processing and transport of
secreted proteins. This finding suggests that heat shock proteins may play an
important role in the pathogenesis of high-altitude pulmonary edema.
Interleukins and leukotrienes are pro-inflammatory cytokines which
contribute to increased endothelial cell permeability and vascular leak. These
mediators, including interleukin- 1 , 6, 8, and 10, and tumor necrosis factor-a
(TNF-a) may be important in the pathogenesis of HAPE191 and ARDS187.
Leukotrienes, generated from arachadonic acid, are also involved in endothelial
activation and act as an important trigger for inflammation. Important genes
involved in leukotriene synthesis include 5-Lipoxygenase-activating protein
(FLAP) and multi-drug associated protein 1 (MRP-1). MRP-1, a protein involved
in translocation of leukotrienes, was found to be present in higher





Increased alveolar concentrations of interleukins have been associated
with both HAPE and ARDS. Furthermore, increased gene expression of IL-1(5
and IL-6 have been linked with acute lung injury in multiple studies178. In this
study, gene expression levels of interleukins, including IL-ip and IL-6 did not
appear to be differentially regulated
in HAPE or AMS, as compared to healthy
controls. However, IL-la and the interleukin 1 receptor antagonist (IL-1RA),
both suspected to contribute to the pathogenesis of acute lung injury, were
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expressed in increased quantities in HAPE. Furthermore, TNF-a-related
proteins were strongly expressed in HAPE.
Plasma membrane glycoprotein CD 14 is found on the surface of
macrophages, and plays a role in the recognition and clearance of apoptotic
cells. CD 14 also acts as a receptor that binds lipopolysaccharide (LPS) and
triggers inflammatory responses; hyperstimulation of CD 14 by LPS can cause
the fatal toxic-shock syndrome (TSS) 192. Alveolar fluid levels of CD 14 are
elevated in patients with ARDS178. In this study, gene expression of CD 14 was
significantly different in HAPE patients and those with AMS (p
=
.0016),
suggesting that CD 14 may play a role in HAPE. It is known that the existence
of upper respiratory tract infections prior to ascent increase the risk of
developing high-altitude pulmonary edema in susceptible patients. Thus, it is
possible that the presence of microbial products in these patients triggers an
innate immune inflammatory response which leads to HAPE.
Nuclear factor-kappa-B (NFKB), also upregulated in HAPE subjects (p
=
1.23xl0-9), is activated by inflammatory cytokines, acute phase proteins,
oxidant-free radicals, and bacterial and viral products. It is found on numerous
cell types expressing cytokines, chemokines, growth factors, acute phase
proteins, and cell adhesion molecules Inappropriate upregulation
of NFKB has
been demonstrated in autoimmune and inflammatory events, including septic
shock and lung fibrosis193
Using the candidate gene approach, Garcia et. al (2006) found a
significant upregulation of the cytokine pre-B-cell colony enhancing
factor
(PBEF) in saline lavage-, sepsis-,
and high-ventilation-induced injury models of
ARDS194. A highly conserved 52 kDa protein, PBEF was originally described as
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a growth factor influential in the maturation of B-cell precursors by enhancing
the effect of IL-7. Prior to this study, PBEF had never previously been described
in the lung. Further studies have also found PBEF to be up-regulated in vitro
models of human epithelial cell lines exposed to mechanical stress and
inflammatory cytokines 195.
PBEF expression in peripheral neutrophils is upregulated by IL- 1 p and
inhibits apoptosis of neutrophils in experimental inflammation and clinical
sepsis188. Following identification as a potential biomarker of ALI, PBEF has
been demonstrated to be significantly increased in serum and bronchoalveolar
lavage fluid of patients with acute lung injury188. These data support the role of
PBEF as a novel inflammatory cytokine which plays an important role in
neutrophil apoptosis, clinical sepsis, and ALI.
In our study, PBEF expression was significantly higher in HAPE+
subjects than in either the AMS+ or AMS- control group (p
= 0.0028; p
=
0.0084). Previous studies have also demonstrated a correlation of caspase-8
and caspase-3 (apoptosis-related cysteine peptidase) activity with inhibition of
apoptosis by PBEF. These data are confirmed by a differential expression of
both caspase-8 and -3 in individuals suffering from HAPE (p
= 0.041 and p
=
3.3x105).
Much research has focused on the role of pulmonary vascular tone in the
pathogenesis of HAPE. Upregulation
of pre-B cell colony enhancing factor is
associated with the conversion of vascular smooth muscle cells (SMCs) from a
proliferative to a non-proliferative contractile
state. Transduced human SMCs
overexpressing the PBEF gene displayed increased intracellular nicotinamide
adenine dinucleotide (NAD+) content and promotes SMC maturation to the
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contractile state. Similarly, PBEF-knockdown SMCs demonstrate lower levels of
NAD+19&.
Myosin light chain kinase (MYLK/MLCK) plays an important role in the
regulation of vascular permeability, angiogenesis, and endothelial apoptosis.
Using the interrogation of known pathways in ALI, MYLK was identified as a
candidate gene in ALI194. In this study, expression levels ofmyosin regulatory
light chain (MLC-2), which is phosphorylated by MLCK in the presence of
calcium and calmodulin, thus increasing smooth muscle contractile activity,
are increased in HAPE (p=4.66x10 4).
Thus, multiple pathways implicated in ARDS have been demonstrated to
be upregulated in a HAPE-susceptible cohort. Many of these genes, including
PBEF are previously undescribed in HAPE. These findings provide further
support to the role of inflammatory cytokines, including interleukin -la and
TNF- a in the pathogenesis of HAPE. Furthermore, differential expression of
important regulators of apoptosis, including CD 14, PBEF, and caspase-3 and -8




The functional annotation tool of the Database for Annotation,
Visualization, and Integrated Discovery (DAVID)197 was used to identify KEGG
pathways statistically overrepresented in the gene expression profiles of
individuals with HAPE. These pathways represent co-occurrence within sets of
genes involved in specific biological pathways which are most likely associated
with the disease pathogenesis.
The most highly associated pathways in HAPE, as compared to AMS+
subjects, are listed in Table I. Those representing the most highly up-regulated
pathways in HAPE vs. healthy controls are listed in Table J.
Table I. Overrepresented Kegg-Pathways HAPE vs AMS+
Pathway Number of Genes p-value
Ubiquitin mediated proteolysis 16 6.85 x 10-6
MAPK signaling pathway 43 8.38 x 10-4
Apoptosis 19 .00197
B-cell receptor signaling pathway 15 .0039
Adherens Junction 16 .0062
WNT signaling pathway 24 .012
Huntington's Disease 8 .012
Long-term potentiation
13 .014
T-cell receptor signaling pathway 17 .016
Natural killer cell-mediated cytotoxicity 21 .019




Phosphatidylinositol signaling system 16 .037
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Table J. Overrepresented Kegg-Pathways HAPE vs AMS-
Pathway Number of Genes p-value
Huntington's Disease 6 0.069591
Aminoacyl-tRNA synthetases 7 0.039535
Insulin signaling pathway 18 0.058623
Regulation of actin cytoskeleton 27 0.018604
Long-term potentiation 16 1.18E-04
FC Epsilon RI signaling pathway 12 0.054001
B-cell receptor signaling pathway 15 9.58E-04
T-cell receptor signaling pathway 18 0.001616
Natural killer cell mediated cytotoxicity 18 0.034409
Folate biosynthesis 8 0.025852
Starch and sucrose metabolism 12 0.042647
Gap junction 14 0.045674
Adherens junction 14 0.010615
Functional pathways involving RhoA and Rho-kinase were strongly
upregulated in subjects with HAPE. These pathways include the WNT signaling
pathway, TGF-(3 signaling pathway, adherens junction, T-cell receptor signaling
pathway, and regulation of the actin skeleton (see Table K).
RhoA and Rho-kinase regulate cytoskeletal change within the WNT
signaling pathway, important in development, stress, and repair (see Figure 5).
RhoA and ROCK are activated downstream ofWNT1 1 and Frizzled to regulate
cytoskeletal change and affect focal adhesion through actin
stress fiber
formation. Through this pathway, RhoA regulates the adhesion ofmonocytes to
activated endothelial cells. This pathway is closely related to the focal adhesion
and the MAPK (mitogen-activated protein kinase) signaling pathways. MAPK is
involved in the cellular response to stress, including irradiation, heatshock,
lipopolysaccharide and reactive oxygen species.




Table K. Functional Pathways involving RhoA and Rho-kinase

















T-cell receptor signaling pathway
Leukocyte transendothelial migration


















Rho/ROCK also play a direct role in the pathway responsible for
regulation of the actin cytoskeleton (see Figure 6). In this pathway, ROCK
regulates myosin light chain phosphatase (MLCP) and directly activates myosin
light chain (MLC), resulting in smooth muscle contraction. Rho also regulates
the actin cytoskeleton through the T-cell receptor signaling pathway (see Figure
7). In this pathway, cell adhesion molecule (CAM) ligands on antigen
presenting cells act upstream of Rho and Cdc42.
Figure 6. Pathway Involved in Regulation of Actin Cytoskeleton
Figure 7. T-Cell Receptor Signaling Pathway














Recent studies have demonstrated that increased phosphorylation of
MLC results in membrane blebbing and apoptosis. When ROCK is activated by
caspases, increased phosphorylation of MLC is observed. Furthermore,
inhibition of ROCK proteins resulted in a decrease in MLC-phosphorylation and
membrane blebbing^s. Through this pathway, both Rho and ROCK also act as
upstream regulators of actin stress fiber polymerization.
The KEGG apoptosis pathway is overrepresented in individuals with
HAPE, as compared to those with AMS. If the monocytes of HAPE-susceptible
individuals are undergoing increased apoptosis, their intracellular contents,
including inflammatory mediators are being released into the serum. This
would further enhance the inflammatory response of other tissues, including
lung endothelium, and act as a stimulant to other monocytes. An initial
difference in cellular response to hypoxia may trigger this self-amplifying event,
thus leading to increased susceptibility to HAPE through apoptosis and release
of inflammatory mediators.
Tumor growth factor-(3 (TGF-(3), an important contributor to the
inflammatory response, acts upstream of RhoA/ROCK (see Figure 8). This
pathway plays an important role in angiogenesis and apoptosis, and is also
associated with the MAPK signaling pathway discussed above. TGF-p1 also
regulates macrophage migration via RhoA. Though migration ofmacrophages
is stimulated following direct treatment with TGF-(3, inactivation of RhoA results
in a decreased cell migratory response to TGF-p1 ™.
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FUTURE DIRECTIONS
This pilot study demonstrates that gene expression differs significantly in
subjects suffering from high-altitude pulmonary edema, acute mountain
sickness, and healthy control subjects. Although evidence has shown that 5
biological cases allows for sufficient power analyses in differential expression
testing, recruiting more HAPE+ subjects would optimize the statistical power in
addition to providing enough cases for classification purposes200.
This research provides a foundation for future studies of gene expression
in altitude induced illness, specifically high-altitude pulmonary edema.
Because microarray measurements of gene expression are only moderately
correlated with final protein product expression levels, mRNA and final protein
product levels must be confirmed with direct measurements. The inherent
microarray false positive error rate will also be resolved by confirmation of
mRNA and protein level differences. Confirmation of mRNA expression of
promising genes will be performed using reverse transcription polymerase chain
reaction (RT-PCR). Additionally, ELIZA and western analysis will be conducted
to confirm expression levels of final protein products.
Furthermore, the importance of specific disease modifying genes,
including those involved in leukotriene synthesis and the Rho/Rho-kinase
pathway can be validated by studying the association between gene variants
and disease susceptibility using linkage analysis.
Multiple pathways and genes implicated in ARDS have been
demonstrated to be upregulated in a HAPE-susceptible cohort. Many of these
genes, including PBEF,
are previously undescribed in HAPE. Furthermore,
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differential expression of important regulators of apoptosis suggests that
inhibition of apoptosis plays a central role in both ARDS and HAPE.
These results provide support for the future study of several
pharmacologic interventions for the prevention and treatment of HAPE. The
important role of leukotrienes in the pathogenesis of HAPE provide further
support for the use of oral leukotriene receptor agonists such as montelukast
sodium (Singulair) for prophylaxis of HAPE. Grissom (2005) studied the effect





9) and did not find an association between urinary
leukotriene excretion and AMS201. Because of a low incidence of AMS (n
=
3),
they were unable to comment on the efficacy of Zileuton for prophylaxis of AMS.
In this study, leukotrienes were differentially expressed in HAPE-susceptible
patients. Agents which block the effects of leukotrienes may be effective in the
prevention of HAPE.
The gene expression data from the current study suggest that the
Rho /Rho-kinase (ROCK) pathway is significantly upregulated in HAPE, and
may play an important role in susceptibility to, and the pathogenesis of HAPE.
Activation of the Rho/ROCK pathway downregulates eNOS expression and
nitric oxide production, both ofwhich are strongly associated with HAPE
susceptibility. Furthermore, inhibition of Rho/ROCK has been shown to
decrease vasoconstriction of the pulmonary vascular bed.
Further studies should be performed to determine the efficacy of a
selective Rho-kinase inhibitor such as Fasudil in the prevention and treatment
of HAPE. Rho-kinase inhibitors influence multiple pathways involved in the
pathogenesis of HAPE, including
nitric oxide production, angiotensin II effects,
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vascular smooth muscle dilatation, sympathetic nerve activation and
endothelin- 1 activity (see Figure 9), thus complementing the therapeutic actions
of a number of different drugs previously studied in HAPE, including ACE-
inhibitors, calcium channel blockers, and 0-blockers.
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Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA)
reductase, have been demonstrated to inhibit Rho-kinase202 as well as
upregulate eNOS203, thereby increasing nitric oxide production and reducing
smooth muscle contraction. Furthermore, statins reduce the systemic
expression of biomarkers of inflammation, including C-reactive protein, tumor
necrosis factor (TNF), and interleukins 1 and 6 (IL-1, IL-6). Monocytes treated
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with lovastatin demonstrated decreased levels of Rho-kinase signaling 204.
Thus, statins may reduce inflammation through modulation of the Rho/Rho-
kinase pathway. Because of these strong associations, the efficacy of statins in
the prophylaxis and treatment of HAPE should be further investigated in
clinical trials.
CONCLUSIONS
Currently, few pharmacologic therapies have been demonstrated to be
effective in the prevention and treatment of HAPE. Current first line treatment
includes descent and oxygen therapy. Calcium-channel blockers such as
nifedipine and phosphodiesterase-V inhibitors such as sildenafil have been
demonstrated to decrease pulmonary artery pressures in individuals with
HAPE. However, both of these drugs have the potential to decrease systemic
blood pressure and oxygen saturation.
This study is the first in which the RhoA/ Rho-kinase pathway has been
described in HAPE. The results of this study provide early evidence that
Fasudil, a selective Rho-kinase inhibitor currently in phase II clinical trials,
may be effective in the prevention and/or treatment of high-altitude pulmonary
edema. Because of the strong association between Rho/ROCK, pulmonary
artery pressures, and susceptibility to high-altitude pulmonary edema, Fasudil
and statins may represent novel and useful therapeutic interventions, the
efficacy ofwhich should be explored in future studies. Furthermore, few
effective prophylactic treatment strategies exist for HAPE. Statins and Fasudil
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may represent pharmacologic interventions effective in both the prevention and
treatment of this life-threatening disease.
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Appendix A. Study Questionnaire
HAPE (High-Altitude Pulmonary Edema) Questionnaire
Name/ Subject ID#
Demographics:
1. Sex: M / F
2. Birth year:
3. a. Height: b. Weight:
4. Ethnicity:
a. American Indian/ Alaska Native
b. Asian
c. Native Hawaiian or other Pacific Islander
d. Black or African American
e. White
f. Hispanic or Latino
5. Please describe your symptoms (i.e. shortness of breath, difficulty




Intermittent While moving uphill
At rest While walking on level ground
b. Cough Extreme weakness/fatigue
None




6. When did your symptoms begin? Date / / and Time
7. Altitude (or location) at onset of symptoms:
8. Sleeping elevation on night prior to onset of symptoms:
9. Maximum altitude attained over prior 48 hours:
10. When did you arrive in Telluride? Date / / and Time_
11. When did you leave your permanent residence for Telluride?
2
Date / / and Time
12. How did you travel to Telluride (fly vs. drive)?
13. Zip Code at your place of permanent residence (where you live for a
majority of the year)
14. What is the highest altitude you have been to (previous to this trip)?
a. Altitude
b. Location
15. Have you ever spent the night at high-altitude (>= 8000ft)?
a. No / Yes
b. If so, how many nights?
c. What altitude were you sleeping at?
16. Have you ever been diagnosed with Acute Mountain Sickness (AMS) in
the past?
a. No / Yes
b. If yes, how many times?
c. In what year(s) was/were the diagnosis made?
d. Where were you diagnosed (i.e., city/ state)
e. What treatment did you receive? ___
f. If known, at what approximate altitude did/ do you begin to experience
symptoms?
g. While at altitude, which of the following symptoms do/did you
experience?
i. Headache: mild /moderate / severe
ii. Nausea or Vomiting
hi. Dizziness or Fatigue
h. If known, what was the highest altitude you attained in the 48 hours
prior to the diagnosis?
17. Have you ever been diagnosed with High-Altitude Pulmonary
Edema
(HAPE) (besides today)?
a. No / Yes
b. If yes, how many times?
c. In what year(s) was/were the diagnosis made?
d. Where were you diagnosed? (i.e., city/ state)
e. What treatment did you receive? .
f. If known, what was the highest altitude you attained in the 48 hours
prior to the diagnosis?
18. Degree of physical activity (> 3x per week) at baseline:
Sedentary/ minimally active (walking, shopping)
Moderately active (active walking, gentle hiking)
Very active (running, vigorous skiing, climbing, active backpacking)
19. Degree of physical activity in the past 48 hours.
Sedentary/ minimally active (walking, shopping)
3
Moderately (active walking, gentle hiking)
Very active (running, vigorous skiing, climbing, active backpacking)
20. Type of activity in the last 48 hours:
a. Skiing (Alpine) f. Walking
b. Skiing (Cross-country) g. Running
c. Climbing h. Snowshoeing
d. Hiking i. Other
e. Shopping
21. What medications have you taken in the last 48 hours? (Please check
all that apply)
a. Acetazolamide (Diamox, Sequels)
b. Ibuprofen (Advil)/ Acetaminophen (Tylenol) / Aspirin (i.e. Motrin) /Aleve, etc.
c. Dexamethasone (Decadron)
d. Nifedipine (Procardia, Adalat, Afeditab, Nifedic, Nifedical)
e. Sildenafil (Viagra) / Vardenafil (Levitra) /Tadalafil (Cialis)
f. Cold /flu/ URI OTC medications
g. Nitric oxide
h. Oxygen
i. Albuterol (Ventolin, Proventil, AccuNeb)
j. Opioid agents (Oxycodone, Codeine, Morphine, Hydromorphone)
k. Other
22. Have you suffered from a URI (flu/cold/ sinus infection) in the past
7 days?
a. Yes/ No
b. If so, how many days ago did your symptoms begin?
c. How many days ago did your symptoms stop?
23. Have you consumed alcohol in the past 48 hours?
a. No / Yes
b. If yes, how many drinks?
24. Do you smoke tobacco?
a. No / Yes
b. If yes, how many packs per day?
25. What medications do you take on a regular basis?
26. Were you treated for any med conditions during
the past year?
27. Do you have any other underlying medical conditions?
4
28. Do you have a known history of:









g. Systemic Inflammatory disease (i.e.
RA, SLE)
h. Chronic oxygen therapy?
i. Seizure disorder?
29. Do you have a family history of:
a. Acute Mountain Sickness?
b. High-Altitude Pulmonary Edema?
c. Coronary Artery Disease/ Heart Attack?
d. Stroke?
e. Pulmonary hypertension?
LAKE LOUISE ACUTE MOUNTAIN SICKNESS QUESTIONNAIRE
Have you experienced any of the following symptoms over the past 48




□ 2 -Moderate Headache
D 3-Severe/ incapacitating Headache
2. GI symptoms?
3 O-None
□ 1 -Poor appetite or nausea
D 2-Moderate nausea or vomiting
D 3-Severe/ incapacitating nausea and vomiting
3. Fatigue/ Weakness?
D O-Not tired or weak
□ 1-Mild fatigue or weakness
D 2-Moderate fatigue or weakness






□ 3-Severe/ incapacitating dizziness or lightheadedness
5. Difficulty Sleeping?
□ O-Slept well
□ 1-Did not sleep well
□ 2-Woke many times/ poor night's sleep
□ 3-Could not sleep at all















1 -While moving uphill





HR <90-100 90-100 >110
RR (at rest) <20 16-30 >30
Cyanosis Dusky nail beds Cyanotic nail beds Cyanotic nail beds
and facial cyanosis
Rales Localized General, not bilateral Bilateral
CNS None Ataxia Ataxia/ stupor/
coma
CXR Minor exudates,
<25% of one lung
field
Some infiltrate
involving 50% of one
lung or bilateral
Bilateral infiltrates
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